(51) International Patent Classification 6 : C07D 233/56, A61K 31/415, C07D 401/06, 403/06, 409/06, 405/06, 233/84, 413/12, 495/04 // (C07D 495/04, 335:00, 333:00)	A1	(11) International Publication Number: **WO 99/28300** (43) International Publication Date: 10 June 1999 (10.06.99)

(54) Title: SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

(57) Abstract

     Compounds having adrenergic activity which are selective agonists for one or both of the α_{2B} and α_{2C} adrenoceptor receptor subtypes in preference to the α_{2A} adrenoceptor receptor subtype; the active compound being selected from the group consisting of compounds having formula (I) wherein the dotted lines represent optional bonds provided that two double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R[1], wherein R[1] is H or lower alkyl, but R[1] is absent when the bond between X and the ring represented by formula (a) is a double bond; Y is O, N, S, $(CR^1{}_2)_y$, wherein y is an integer of from 1 to 3, $-CH=CH-$ or $-Y^1CH_2-$, wherein Y^1 is O, N or S; x is an integer of 1 or 2, wherein x is 1 when R[2], R[3] or R[4] is bound to a saturated carbon atom and x is 2 when R[2], R[3] or R[4] is bound to a saturated carbon atom; R[2] is H, lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a saturated carbon atom, R[2] may be oxo; R[3] and R[4] are, each, H, lower alkyl, hydroxy, lower alkoxy, or phenyl or, together, are $-(C(R^2)x)z-$; $-Y^1(C(R^2)x)z'-$; $-Y^1(C(R^2)x)yY^1-$; $-(C(R^2)x)-Y^1-(C(R^2)x)-$; $-(C(R^2)x)-Y^1-(C(R^2)x)-(C(R^2)x)-$ and $-Y^1-(C(R^2)x)-Y^1-(C(R^2)x)-$ wherein z is an integer of from 3 to 5, z' is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R3 or R4 to form a condensed ring structure and the rings formed may be totally unsaturated, partially unsaturated, or totally saturated; and being useful for treating muscle spasticity. including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases, memory and cognition deficits, psychoses including manic disorders and anxiety, hypertension, cardiac ischemia, congestive heart failure, and nasal congestion without sedating or cardiovascular side effects.

BEST AVAILABLE COPY

SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS

5

1.   Field of the Invention

The present invention is directed to a method of treating glaucoma or elevated intraocular pressure and other diseases with substantially reduced cardiovascular or sedative side effects by administering to

10   mammals including humans, compounds which are selective agonists of the $\alpha 2B$ alone or $\alpha 2B$ and $\alpha 2C$ adrenergic receptor subtypes and which lack substantial activity at the $\alpha 2A$ receptor subtype. The present invention is also directed to novel compounds and pharmaceutical compositions adapted for administering said compounds to mammals, including

15 · humans.

2.   Brief Description of the Prior Art

Compounds which have adrenergic activity are well known in the art, and are described in numerous United States and foreign patents and in scientific publications. It is generally known and accepted in the art that

20   adrenergic activity is useful for treating animals of the mammalian species, including humans, for curing or alleviating the symptoms and conditions of numerous diseases and conditions. In other words, it is generally accepted in the art that pharmaceutical compositions having an adrenergic compound or compounds as the active ingredient are useful for treating

25   glaucoma, chronic pain, nasal congestion, high blood pressure, congestive heart failure and inducing anesthesia.

The two main families of adrenergic receptor are termed alpha adrenergic receptors and beta adrenergic receptors in the art, and each of these two families is known to have subtypes, which are designated by

2

letters of the alphabet, such as α2A, α2B. See the article by Bylund et al,
Pharmacol Rev. 46, pp. 121-136(1994).

SUMMARY OF THE INVENTION

5   It has been discovered in accordance with the present invention that
adrenergic compounds which act selectively, and preferably even
specifically as agonists of the α2B or α2B / α2C (hereinafter referred to as
α2B or α2B/2C) receptor subtypes in preference over the α2A receptor
subtype, possess desirable therapeutic properties associated with
10   adrenergics but without having one or more undesirable side effects such
as changes in blood pressure or sedation. For the purposes of the present
invention, a compound is defined to be a specific or at least selective
agonist of the α2B or α2B/2C receptor subtype(s) if the compound is at
least approximately ten times more potent as an agonist at either the α2B
15   and α2C or both receptor subtypes than at the α2A receptor subtype, or if
the difference in the compound's efficacy at the α2B and α2B/2C receptor
relative to the α2A receptor is greater than 0.3 and its efficacy at the
α2A receptor is ≤ 0.4.

        Accordingly, the present invention relates to methods of treating
20   animals of the mammalian species, including humans, with a
pharmaceutical composition comprising one or more specific or selective
α2B or α2B/2C adrenergic agonist compounds as the active ingredient, for
treatment of the many diseases or conditions against which alpha
adrenergic compounds are useful, including without limitation glaucoma,
25   reducing elevated intraocular pressure, chronic pain, diarrhea, and nasal
congestion. In addition, the compounds of this invention are useful for

treating muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases including optic neuropathy, spinal ischemia and stroke, memory and cognition deficits, attention deficit disorder,

5   psychoses including manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia and nasal congestion.

The present invention is also directed to the pharmaceutical compositions used in the above-noted methods of treatment.

The present invention particularly covers methods for treating

10   diseases and conditions where adrenergic compounds are effective for treatment, but their use is limited because of their generally known side effects.

DETAILED DESCRIPTION OF THE INVENTION

15   Compounds which are used in the pharmaceutical compositions and methods of treatment of the present invention are selective or specific agonists of the α2B or α2B/2C adrenergic receptor subtypes, in preference over the α2A receptor subtype. In accordance with the present invention, a compound is considered a selective α2B or α2B/2C agonist if that

20   compound's difference in efficacy as an agonist of the α2B or α2B/2C receptor subtype(s) compared to the α2A receptor subtype is greater than 0.3 and its efficacy at the α2A receptor subtype is ≤ 0.4 and/or it is at least approximately 10 times more potent. Preferably, the compounds utilized in accordance with the present invention are specific agonists of the α2B or

25   α2B/2C receptor subtypes. Specifically, in this regard, a specific agonist is defined in the sense that a specific α adrenergic agonist does not

4

act as an agonist of the α2A receptor subtype to any measurable or biologically significant extent.

A set of agents has been discovered that are functionally selective for the α2B or α2B/2C - subtypes of said adrenergic receptors. This

5   preferential activity can be determined in a variety of functional assays such as Cyclic AMP Production, Shimizu et al, *J. Neurochem*. 16, pp. 1609- 1619 (1969); R-SAT (Receptor Selection and Amplification Technology), Messier et al, *Pharmacol. Toxicol*. 76, pp. 308-311(1995) and the Cytosensor microphysiometer, Neve et al, *J. Biol. Chem*. 267, pp. 25748-25753, (1992)

10   using cells that naturally express individual subtypes or have had one of the subtypes introduced. The cells or recombinant receptors used should be human or from a species that has been shown to have a similar pharmacology. In the study below, the RSAT assay on cells that have been transiently transfected with the human α2A (c10 gene), rat α2B (RNG gene)

15   and human α2C (c4 gene) receptors was used. The rat α2B receptor has been shown to have a pharmacology that corresponds to the human α2B receptor (see, for example, Bylund et al., *Pharmocol, Rev*. 46, pp. 127- 129(1994)).

In the treatment of glaucoma, particularly, topical administration

20   may be used. Any common topical formulation such as a solution, suspension, gel, ointment, or salve and the like may be applied to the eye in glaucoma and dermally to treat other indications. Preparation of such topical formulations are well described in the art of pharmaceutical formulations as exemplified, for example, by Remington's Pharmaceutical

25   Science, Edition 17, Mack Publishing Company, Easton, Pennsylvania.

5

If the drug is to be administered systemically, it may be confected as a powder, pill, tablet or the like or as a syrup or elixir for oral administration. For intravenous, intraperitoneal, intrathecal or epidural administration, the compound will be prepared as a solution or suspension capable of

5   being administered by injection. In certain cases, it may be useful to formulate these compounds in suppository or as an extended release formulation, including the dermal patch form, for deposit on or under the skin or for intramuscular injection.

Treatment of glaucoma or any other indications known or

10   discovered to be susceptible to treatment by adrenergic compounds will be effected by administration of therapeutically effective dose of one or more compounds in accordance with the instant invention. A therapeutic concentration will be that concentration which effects reduction of the particular condition, or retards its expansion. In certain instances, the drug

15   potentially could be used in a prophylactic manner to prevent onset of a particular condition. A given therapeutic concentration will vary from condition to condition and in certain instances may vary with the severity of the condition being treated and the patient's susceptibility to treatment. Accordingly, a given therapeutic concentration will be best determined at

20   the time and place through routine experimentation. However, it is anticipated that in the treatment of, for example, glaucoma, that a formulation containing between 0.001 and 5 percent by weight, preferably about 0.01 to 3% will usually constitute a therapeutically effective concentration. If administered systemically, an amount between 0.001 and

25   50 mg per kg, preferably between 0.001 and 10 mg per kg body weight per

6

day, but most preferably about 0.01 to 1.0 mg/kg, will effect a therapeutic result in most instances.

Because the α2B and α2B/2C specific selective agonist compounds lack substantial α2A side effects, treatments of diseases or conditions with
5   such compounds in accordance with the present invention is advantageous, particularly when the treatment is directed to a human having cardiovascular problems.

The general structures of exemplary specific α2B and α2C agonist or selective α2B and α2B/2C agonist adrenergic compounds which are used
10   in the pharmaceutical compositions and methods of treatment of the present invention are provided by general Formulas, below.

In one aspect of the invention, a compound having selective agonist activity at the α2B or α2B/2C adrenergic receptor subtype(s) as compared to the 2A adrenergic receptor subtype is represented by the general
15   formula

I

wherein the dotted lines represent optional bonds provided that two
20   double bonds may not share a common carbon atom; R is H or lower alkyl; X is S or C(H)R', wherein R' is H or lower alkyl, but R' is absent when the bond between X and the ring represented by

is a double bond; Y is O, N, S, $(CR^1_2)_y$, wherein y is an integer of from 1 to 3,
-CH=CH- or -Y'CH$_2$-, wherein Y' is O, N or S; x is an integer of 1 or 2,
wherein x is 1 when R^2, R^3 or R^4 is bound to an unsaturated carbon atom

5   and x is 2 when R^2, R^3 or R^4 is bonded to a saturated carbon atom; R^2 is H,
lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a
saturated carbon atom, R_2 may be oxo; R_3 and R_4 are, each, H, lower alkyl,
hydroxy, lower alkoxy, or phenyl or, together, are $-(C(R^2)x)z-$; $-$
$Y'(C(R^2)x)z'-$; $- Y' (C(R^2)x)y Y'-$; $-(C(R^2)x)- Y'-(C(R^2)x)-$; $- (C(R^2)x)- Y'-$

10   $(C(R^2)x)-(C(R^2)x)-$ and $- Y'-(C(R^2)x)- Y'-(C(R^2)x)-$ wherein z is an integer of
from 3 to 5, z' is an integer of from 2 to 4 and x and y are as defined above,
and further either end of each of these divalent moieties may attach at
either R3 or R4 to form a condensed ring structure shown generally as

15

and the rings formed may be totally unsaturated, partially unsaturated, or

20   totally saturated provided that a ring carbon has no more than 4 valences,
nitrogen no more than three and O and S have no more than two.

In another aspect of the invention in the above compound is
represented by the formula

25

8

wherein X may be C(H)R^1 and R^1 is H.

In said compound of formula II, R$_2$ may be H and

5

may represent a furanyl radical.

In such furanyl derivatives of Formula II, R^3 and R^4 together may be (CH)$_4$, or R^3 may be H and R^4 may be t-butyl, or R^3 and R^4 may be H, or R^3 may be H and R^4 may be methyl or ethyl.

10   Alternatively, in the compound of Formula I, R^1 may be methyl and

may represent a furanyl radical.

15   Alternatively, in said compounds of Formula II, R^2 may be H and

may represent a thienyl radical.

20   In such thienyl derivatives of Formula II, R^3 and R^4 , together, may represent (CH$_2$)$_4$, or R^3 may be phenyl and R^4 may be H, or R^3 and R^4, together, may represent (CH$_2$)$_3$S, or R^3 and R^4 may be H, or R^3 and R^4, together, may represent (CH)$_4$, or may be R^3 may be H and R^4 may be methyl, or R^3 may be bromo and R^4 may be H, or R^3 may be hydrogen and

25   R^4 may be chloro, or R^3 may be methyl and R^4 may be hydrogen.

Alternatively, in the compounds of Formula II

may represent a cyclohexyl radical.

In such cyclohexyl derivatives of Formula II, R^2 may be hydrogen and R^3 and R^4 may, together, represent $(CH)_4$, or R^2 may be oxo and R^3 and R^4, together, may be $(CH)_4$, or R^2 may be hydrogen or oxo and R^3 and R^4, together, may represent $(CH)_2S$, or R^2 may be hydrogen and R^3 and R^4 may, together, represent $(CH_2)_4$, forming an octahydronaphthalene, or R^2 may be oxo and R^3 and R^4 may, together, represent $(CH_2)_4$, or R^2 may be oxo and R^3 and R^4, together, may represent $(CH)_2C(CH_3)(CH)$, or R^2 may be hydrogen and R^3 and R^4, together, may represent $S(CH_2)_2$, or R^2 , R^3 and R^4 may be H, or R^2 may be oxo and R^3 and R^4, together, may represent $(CH)_2 C(OCH_3)CH$, or R^3 and R^4 together may represent $-Y^1-C(R_2)_x-C(R_2)_x-$ Y^1-wherein Y^1 is N, forming a tetrahydroquinoxaline wherein R^2 may be hydrogen or oxo. Alternatively, in the compounds of Formula II

may represent a tetrahydroquinoline radical wherein R^3 and R^4 together are $-Y^1-C(R_2)_x-C(R_2)_x-C(R_2)_x-$ wherein Y^1 is N. In such tetrahydroquinoline derivatives $(R^2)_x$ may be hydrogen or oxo; or may represent a tetrahydro-isoquinoline radical wherein R^3 and R^4 together are $-C(R_2)_x-Y^1-C(R_2)_x-C(R_2)_x-$ wherein Y^1 is N and $(R^2)_x$ may be hydrogen or oxo.

Alternatively, in the compounds of Formula II

10

may represent a cyclopentyl radical.

In such cyclopentyl derivatives of Formula II, R^2 may be H and R^3 and R^4, together, may represent $(CH)_4$, or R^2 may be oxo and R^3 and R^4, together, may represent $(CH)_4$, or R^2 may be hydrogen and R^3 and R^4, together, may represent $(CH_2)_3$.

In another aspect of the invention, Y is $(CH_2)_3$ and X may be CH and R^2 may be oxo or X may be CH_2 and R^2 may be H. Alternatively, R^3 and R^4, together, may represent $(CH)_4$, Y may be $CH_2C(CR^1_2)_2$ wherein R^1 is hydrogen, or Y may be -CH2C(Me)- and R^2 may be hydrogen or oxo.

Finally, in the compounds of Formula II

may represent a phenyl radical.

In such phenyl derivatives of Formula I, X may be CH_2, R maybe H or CH_3, R^2, R^3 and R^4 may be H, or R^3 and R^4, together, represent $O(CR^2)_2O$ to provide a 1,4-benzodioxan derivative, or alternatively, X may be S and R^2, R^3 and R^4 may be H.

In another aspect of the invention, said compound has the formula

III

wherein Y is S or O.

In such compound of Formula III, X may be C(H)R^1, R, R^1 , R^2, R^3 and R^4 may be H and Y may be O or S.

In another aspect of the invention, said compound has the formula

IV

and R^3 and R^4, together, represent (CH)$_4$.

In such compounds of Formula IV, Y^1 may be O, R^2 may be oxo and X is CH or CH$_2$, or one of R^2 is hydroxy and the other may be H, or R^2 may be H.

In such compounds of Formula IV, Y^1 may be S, X may be CH$_2$ and R^2 may be oxo, or R^2 may be H and X may be CH and R^2 may be oxo.

In another aspect of the invention, the compound having selective activity at the 2B or 2B and 2C adrenergic receptor subtype(s) as compared to the 2A adrenergic receptor subtype is represented by the formula

V

alternatively W is a bicyclic radical selected from the group consisting of

wherein R^5, R^6, R^7 and R^8 are selected from the group consisting of H and lower alkyl provided that at least one of R^5 and R^6 or R^6 and R^7 are $OC(R^9)C(R^9)N(R)$ to form a condensed ring with

wherein R^9 is H, lower alkyl or oxo;

and

wherein R^{10} is H, lower alkyl, phenyl or lower alkyl substituted phenyl, and Z is O or NH. Compounds wherein W is norbornyl are disclosed and claimed in commonly assigned co-pending application 09/003902, filed on 7 January, 1998, which is hereby incorporated by reference in its entirety.

In one aspect of the invention Z may be O and W may be

13

and R^{10} may be selected from the group consisting of H, phenyl and o-methylphenyl, e.g. R^{10} may be o-methylphenyl.

In another aspect of the invention W may be

5   wherein Z may be NR, R may be methyl or hydrogen, one of $(R^9)_x$ may be H and R^5 may be H.

Alternatively, W may be

wherein R may be H and R^8 may be methyl.

10   The invention is further illustrated by the following examples (including general synthetic schemes therefore) which are illustrative of

14

various aspects of the invention and are not intended as limiting the scope
of the invention as defined by the appended claims.

Example A

5   Synthesis of 1-dimethylsulfamoyl-2-t-butyldimethylsilyl-5-
imidazolecarboxaldehyde:

Procedure -

10   Imidazole (1) (20.0g, 0.29 mol), triethylamine (41.0mL, 0.29 mol) and N,N-
dimethylsulfamoyl chloride (31.6mL, 0.29 mol) were added to 320mL of
benzene. The reaction was stirred for 48h at room temperature (rt) and
then filtered. The filtrate was collected and concentrated under reduced
pressure. Vacuum distillation of the crude product (~0.5 mmHg, 115°-

15   118°C) afforded 38.7g (76%) of a clear and colorless oil. Upon cooling the
product solidifies to give white crystals (2). 1-(Dimethylsulfamoyl)
imidazole (2) (18.8g, 0.11 mol) was added to 430mL of tetrahydrofuran
(THF). The solution was cooled to –78° C. A solution of n-butyl lithium (n-
BuLi) in hexane (1.6M, 70.9 mL, 0.11 mol) was added dropwise to the

15

reaction flask. Upon completion, the reaction was stirred for 1h at -78°C. t-Butyldimethylsilylchloride (17.8g, 0.12 mol) in 50mL of THF was added via cannula to the reaction. After the addition was completed the reaction mixture was warmed slowly to rt and then stirred for 24h . The reaction

5   was diluted with water and the organic layer separated. The organic phase was washed with brine and then dried over sodium sulfate. The mixture was filtered and the filtrate concentrated under reduced pressure. Column chromatography (20% ethyl acetate/ hexane as eluant) afforded a light yellow solid. Recrystallization from pentane gave 30g (94%) of white

10   crystals (3).

1-Dimethylsulfamoyl-2-t-butyldimethylsilyl imidazole (3) (5.0g, 17.3 mmol) was added to 100mL of THF. The solution was cooled to -20°C. A solution of secondary butyl lithium (s-BuLi) in hexane (1.3M, 14.6mL, 19 mmol) was added dropwise to the reaction flask. Upon completion the reaction was

15   stirred for 1h at -20°C. 8 mL of dimethylformamide (DMF) was added to the reaction and then stirred at rt for 3.5h. The reaction was diluted with water and the organic layer separated. The organic phase was washed with brine and then dried over sodium sulfate. The mixture was filtered and the filtrate concentrated under reduced pressure. Column

20   chromatography (20% ethyl acetate/ hexane) afforded a light yellow oil. Upon cooling the product solidifies to give yellow crystals of 1-dimethylsulfamoyl-2-t-butyldimethylsilyl-5- imidazolecarboxaldehyde (4).

25

Example B-1

16

Procedure for Preparation of 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphthalen-
2-ylmethyl)-1H-imidazole, hydrogen chloride salt:

Procedure -

7-Methoxy-1-tetralone (1) (1.5g, 8.5 mmol) and 1-dimethylsulfamoyl-
2-t-butyldimethylsilyl-5- imidazolecarboxaldehyde (2) (2.7g, 8.5 mmol)
were added to 8.5 mL of a 40% solution of sulfuric acid. The reaction was

10   heated for 24h at 90°C. After cooling to rt, the reaction was made basic
with excess concentrated ammonium hydroxide. The mixture was
extracted twice with THF. The organic layers were combined and washed

17

with brine. The organic layer was separated and dried over sodium
sulfate. The mixture was filtered and the filtrate concentrated under
reduced pressure to afford 2.7g of a yellow solid (3) comprising 3-(3H-
imidazole-4(5)ylmethylene)-7-methoxy chroman-4-one. The crude product

5   was suspended in 100mL of ethanol and a palladium on carbon catalyst
(10%, 0.27g) added. The mixture was shaken in a Parr hydrogenator
apparatus while under 40 psi of hydrogen. After 19h the reaction mixture
was filtered through Celite and the filtrate concentrated under reduced
pressure. Column chromatography with 7% methanol in chloroform

10   afforded 1.05g (46%) of a tan color solid comprising 2-[3H-Imidazole-4(5)-
ylmethyl]-7-methoxy-3,4-dihydro-2H-naphthalen-1-one (4)(B-1a). (4) (0.5g,
1.95 mmol) was added to 20mL of methanol. Sodium borohydride (74mg,
1.95 mmol) was added to the solution. After stirring for 2.5h at rt the
reaction mixture was quenched with water. The reaction mixture was then

15   extracted twice with ethyl acetate. The organic layers were combined and
washed with brine. The organic layer was separated and dried over
sodium sulfate. The mixture was filtered and the filtrate concentrated
under reduced pressure to afford 0.5g of a white solid (5) comprising 2-
[3H-Imidazole-4(5)-ylmethyl]-7-methoxy-3,4-dihydro-2H-naphthalen-1-ol.

20   The crude product was dissolved in 26mL of dichloromethane.
Triethylsilane (2.5mL, 15.6 mmol) and trifluoroacetic acid (4.8mL, 62.3
mmol) were added and the reaction stirred at rt for 22h. The reaction was
made basic with 2N NaOH and the organic layer separated and washed
with brine. The solution was dried over sodium sulfate. The mixture was

25   filtered and the filtrate concentrated under reduced pressure. Column
chromatography with 7% methanol in chloroform afforded 0.39g (83%) of a

18

tan color oil (6). The product was dissolved in methanol and an excess of hydrogen chloride (HCl) in ether was added. The solution was concentrated under reduced pressure to yield 0.3g of a tan color solid. Column chromatography with 7% methanol in chloroform afforded 0.25g

5   (46%) of 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole, hydrogen chloride salt (B-1) as white crystals (7) after recrystallization from a mixture of acetone and methanol.
^{1}H NMR (300 MHz, CD$_3$OD) 8.83 (s, 1H), 7.38 (s, 1H), 6.95 (d, 1H, J=8.5Hz), 6.66 (d, 1H, J=8.4Hz), 6.57 (s, 1H), 3.73 (s, 3H), 2.71-2.81 (m, 5H), 2.43-2.52

10   (m, 1H), 1.90-2.14 (m, 2H), 1.40-1.51 (m, 1H).

Following the procedure of Example B-1 various fused ring compounds are reacted to yield the imidazole derivatives listed below.

15   **Example B-2(a-d)**

4-chromanone   (2a)   3-(3H-imidazol-4(5)-ylmethylene)chroman-4-one

                          (2b)   3-(3H-imidazol-4(5)-ylmethyl)chroman-4-one
20

                          (2c)   3-(3H-imidazol-4(5)-ylmethyl)chroman-4-ol

25   (2d)   4(5)-chroman-3-ylmethyl-1H-imidazole

                                          Example B-3(a-b)

1-tetralone   (3a)   2-(3H-imidazol-4(5)-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one
30

                          (3b)   4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole

19

Example B-4(a-b)

4-methyl-1-tetralone   (4a)   4(5)-(4-methyl-1,2,3,4-
                             tetrahydronaphthalen-2-
                             ylmethyl)-1H-imidazole

                      (4b)   2-(3H-imidazol-4(5)-ylmethyl)-4-methyl-
                             3,4-dihydro-2H-naphthalen-1-one

Example B-5(a-b)

Thiochroman   (5a)   3-(3H-imidazol-4(5)-
                             ylmethylene)thiochroman-4-one

                      (5b)   3-(3H-imidazol-4(5)-
                             ylmethyl)thiochroman-4-one

Example B-6

The hydrogen chloride salt of the previous compound is prepared
by step 5 of the method of Example B-1, above.

Thiochroman   4(5)-thiochroman-3-ylmethyl-1H-
                             imidazole

Example B-7(a-c)

1-indanone   (7a)   2-(3H-imidazol-4(5)-ylmethylene)indan-
                             1-one

                      (7b)   2-(3H-imidazole-4(5)-ylmethyl)indan-1-
                             one

                      (7c)   4(5)-indan-2-ylmethyl-1H-imidazole

Example B-8(a-b)

20

| 7-methyl-1-tetralone | (8a) | 2-(3H-imidazol-4(5)-ylmethyl)-7-methyl- 3,4-dihydro-2H-naphthalen-1-one |

5

| | (8b) | 4(5)-(7-methyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole |

The hydrogen chloride salt of this compound is prepared by the method of
10   Example B-6.

Example B-9(a-c)

| 4-keto-4,5,6,7-tetra-hydrothianaphthene | (9a) | 4(5)-(4,5,6,7-tetrahydro-benzo[b]thiophen-5-ylmethyl)-1H-imidazole |
15

The hydrogen chloride salt of this compound is prepared by the method of
Example B-6.

| | (9b) | 5-(3H-imidazol-4(5)-ylmethyl)-6,7-dihydro-5H-benzo[b]thiophen-4-one |
20

The hydrogen chloride salt of this compound is prepared by the method of
Example B-6.

25 | | (9c) | 5-(octahydrobenzo[b]thiophen-5-ylmethyl)-1H-imidazole |

Example B-10

30 | 4,4-Dimethyl-1-tetralone | | 4(5)-(4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole |

Example B-11(a-b)

35

| 1-Benzosuberone | (11a) | 4(5)-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl)-1H-imidazole |

21

(11b)   6-(1H-imidazol-4(5)-ylmethylene)-6,7,8,9-
         tetrahydrobenzocyclohepten-
         5-one

5   **Example C-1**

Procedure for Preparation of 4(5)-thiophen-3-ylmethyl-1H-imidazole :

Procedure -

1-(Dimethylsulfamoyl)imidazole (1) (2.0g, 11.4 mmol) is taken up in

10   42mL of anhydrous THF and cooled to -78°C. n-BuLi (6.6mL, 10.6 mmol) is

added dropwise to the solution of (1). The resultant solution is stirred at -

78°C for 30 min. Tert-butyldimethylsilylchloride (TBSCl) (1.6g, 10.6 mmol)

in 8mL of THF is added to the reaction. The reaction is warmed to rt and

stirred overnight. The next day the reaction is cooled to -20°C and 7.3mL

22

(11.6 mmol) of n- BuLi added. After stirring at -20°C for 45 min, 3-

thiophene carboxaldehyde (2) (1.0mL, 11.6 mmol) is added to the reaction

mixture. Then reaction is warmed to rt and stirred overnight. The next

day the reaction is quenched with water and diluted with ethyl acetate.

5   The organic layer is washed with water followed by brine. The organic

phase is dried over sodium sulfate and the solvent removed under reduced

pressure. Flash chromatography (2:5 ethyl acetate/ hexane) affords 3.0g

(7.5 mmol) of 2-(t-butyldimethylsilyl)-5-(hydroxythiophen-2-

ylmethyl)imidazole-1-sulfonic acid dimethylamide (3). (3) (1.5g, 3.74

10   mmol) is taken up in 37mL of THF. A 1M solution of tetra-n-

butylammonium fluoride (TBAF) in THF (4.1mL, 4.1 mmol) is added

dropwise to the solution of (3). The reaction is stirred overnight at rt. The

next day the reaction is quenched with water and then extracted with ethyl

acetate. The organic layer is washed with water followed by brine. The

15   organic phase is dried over sodium sulfate and the solvent removed under

reduced pressure. 0.94g (3.3 mmol) of 5-(hydroxythiophen-2-

ylmethyl)imidazole-1-sulfonic acid dimethylamide (4) is recovered. (4)

(0.5g, 1.74 mmol) is taken up in 23mL of dichloromethane, to the solution is

added 2.2 mL (13.9 mmol) of triethylsilane and 4.3 mL (55.7 mmol) of

20   trifluoroacetic acid. The reaction is stirred at rt overnight and then

quenched with water and neutralized with solid sodium bicarbonate. The

organic layer is washed with water followed by brine. The organic phase

is dried over sodium sulfate and the solvent removed under reduced

pressure. Flash chromatography using a 1:1 mixture of ethyl acetate and

25   hexane affords 0.42g (1.55 mmol) of 5-(thiophen-2-ylmethyl)imidazole-1-

sulfonic acid dimethylamide (5). (5) (0.42g, 1.55 mmol) is taken up in 10mL

of a 1.5N HCl solution and heated at reflux for 3h and then stirred at rt

overnight. The reaction is diluted with ethyl acetate, neutralized with solid

sodium bicarbonate and then made basic with 2N NaOH. The organic

layer is washed with water followed by brine. The organic phase is dried

5   over sodium sulfate and the solvent removed under reduced pressure.

Flash chromatography using a 10:1 mixture of chloroform and methanol

affords 0.17g (1.0 mmol) of 4(5)-thiophen-3-ylmethyl-1H-imidazole (6) (C-

1).

^{1}H NMR (300 MHz, CD$_3$OD) 7.52 (s, 1H), 7.25-7.27 (m, 1H), 6.96-7.01 (m,

10   2H), 6.77 (s, 1H), 3.98 (s, 2H).

Example C-2

The 2-carboxaldehyde isomer of 3-thiophene carboxaldehyde is substituted

into the method of Example C-1 to yield 4(5)-thiophen-2-ylmethyl-1H-

imidazole

15   ### Example C-3

5-Methyl-2-thiophene carboxaldehyde of 3-thiophene carboxaldehyde is

substituted into the method of Example C-1 to yield 4(5)-(5-

methylthiophen-2-ylmethyl)-1H-imidazole

Example C-4

20   5-Chloro-2-thiophene carboxaldehyde of 3-thiophene carboxaldehyde is

substituted into the method of Example C-1 to yield 4(5)-(5-chlorothiophen-

2-ylmethyl)-1H-imidazole

Example C-5

2-Furan carboxaldehyde is substituted into the method of Example C-1 to

25   yield 4 (5)-furan-2-ylmethyl-1H-imidazole

24

Example C-6

3-Furan carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-furan-3-ylmethyl-1H-imidazole

Example C-7

5 5-Methyl-2-furan carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-(5-methylfuran-2-ylmethyl)-1H-imidazole

Example C-8

Benzaldehyde is substituted into the method of Example C-1 to yield 4(5)-benzyl-1H-imidazole

10 ### Example C-9

2-Thianaphthene carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-benzo[b]thiophen-2-ylmethyl-1H-imidazole

Example C-10

2-Benzofuran carboxaldehyde is substituted into the method of Example C-
15 1 to yield 4(5)-benzofuran-2-ylmethyl-1H-imidazole

Example C-11

5-Ethyl-2-furan carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-(5-ethylfuran-2-ylmethyl-1H-imidazole

Example C-12

20 4-Bromo-2-thiophene carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-(4-bromothiophen-2-ylmethyl)-1H-imidazole

Example C-13

4-Phenyl-2-thiophene carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-(4-phenylthiophen-2-ylmethyl)-1H-imidazole

25 ### Example C-14

25

4-Methyl-2-thiophene carboxaldehyde is substituted into the method of Example C-1 to yield 4(5)-(4-methylthiophen-2-ylmethyl)-1H-imidazole,hydrochloride salt

5   **Example D-1**

Procedure for Preparation of oxazolidin-2-ylidene-(3-phenyl bicyclo[2.2.1]hept-2-yl) amine :

10   Procedure -

The *endo exo* relative stereochemistry of the compound was prepared, by making the β-nitrostyrene as shown above. Treatment of a methanol solution of benzaldehyde (10g, 94.3 mmole) with nitromethane (51ml, 943 mmol) in the presence of sodium hydroxide (3N in methanol to

15   pH=8) afforded the nitro alcohol in 60% yield. Dehydration of the alcohol was effected by treatment with methanesulfonyl chloride (3.56g, 31.1mmole) followed by triethylamine (6.3g, 62.2 mmol) in

26

dichloromethane (35ml) to give 97% yield of product. Kugelrohr
distillation was done to purify compound. Construction of the
bicyclo[2.2.1]heptane skeleton was carried out in one step. The Diels-Alder
reaction was conducted by warming the nitrostyrene (4.5g, 30.2 mmole)
5   with cyclopentadiene (3.98g, 60.4 mmole) in 1, 2-dichloroethane (10ml).
The Diels-Alder reaction proceeds in approximately a 3:1 endo:exo nitro
ratio.   Both the ratio and relative stereochemistry was demonstrated
through x-ray analysis.   Reduction of both the nitro group and the olefin
was carried out under an atmosphere of hydrogen in the presence of 10%
10   by weight palladium on charcoal. Separation of isomers was conveniently
carried out at this stage using flash chromatography with 5% ammonia-
saturated methanol in dichloromethane. The amine (0.7g, 3.74 mmole) was
treated first with chloroethylisocyanate (0.38ml, 4.49mmole) to afford the
chloroethylurea, which was then warmed in the presence of aqueous
15   NaHCO$_3$ solution to afford oxazolidin-2-ylidene-(3-phenyl bicyclo[2.2.1]
hept-2-yl) amine (D-1) in 51% yield.

^{1}H NMR (300 MHz, CDCl$_3$) d 1.36-1.80 (m, 6H), 2.14 (d, 1H, J=4.40Hz), 2.37
(s, 1H), 2.65 (s, 1H), 3.71-3.78 (m, 2H), 3.95-3.98 (m, 1H), 4.19-4.25 (t, 2H,
J=17.15Hz, J=8.36Hz), 7.17-7.29 (m, 5H).

20   Example D-2

Oxazolidin-2-ylidene-(3-o-tolyl bicyclo[2.2.1]hept-2-yl)amine is prepared
by substituting o-methyl β-nitrostyrene in the method of D-1

                                Example D-3

Bicyclo[2.2.1]hept-2-yl oxazolidin-2-ylidene amine is prepared by substituting
25   nitroethene in the method of D-1

27

Example E-1

Procedure for Preparation of imidazolidin-2-ylidene-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)amine:

5

Procedure -

To 2-amino-4-nitrophenol (1) (4.00g, 25.95 mmol), triethylamine (15.20mL, 109.0 mmol) and 4-dimethylaminopyridine (0.063g, 0.52 mmol) slurried in anhydrous CH_2Cl_2 (250mL) at 0°C under argon added

28

chloroacetyl chloride (2.27 mL, 28.55mmol) via syringe. After refluxing for

72h pure product was filtered off and washed with water. The mother

liquor was washed successively with phosphoric acid (0.5M), saturated

sodium bicarbonate, water and brine and then dried over MgSO$_4$. This

5   solution was adhered to silica and purified by flash chromatography on

silica with hexane/ethyl acetate (4:6) to give additional product. The

combined solids were dried in vacuo to give pure 6-nitro-4H-

benzo[1,4]oxazin-3-one (2) (4.12g) in 82% yield. To a slurry of (2) (1.49g,

7.65 mmol) in anhydrous THF (40mL) under argon in a 2-neck round-

10   bottom flask equipped with a reflux condenser was added borane-

dimethyl sulfide complex (15.3mL, 30.62 mmol). The mixture was heated

at reflux until starting material was no longer observed via thin layer

chromatography (2h). The reaction mixture was cooled to rt and carefully

quenched by the dropwise addition of methanol. The resulting mixture

15   was then refluxed an additional 10 minutes. The crude reaction mixture

was concentrated in vacuo and purified by flash chromatography on silica

with hexane/ethyl acetate (8:2) to give pure 6-nitro-3,4-dihydro-2H-

benzo[1,4]oxazine (3) (1.36g) as an orange solid in 99% yield. To (3)

(0.032g, 0.178mmol) and formalin (37% in H$_2$O, 0.20 mL, 2.67 mmol) in

20   anhydrous acetonitrile (1.5mL) at ambient temperature was added sodium

cyanoborohydride (0.034g, 0.534 mmol). This solution was stirred for 30

min before adding glacial acetic acid (0.032mL, 0.534 mmol). The resulting

mixture was stirred an additional 16h. The organics were taken up in

diethyl ether and washed successively with NaOH (2N) and brine, dried

25   over MgSO$_4$ and concentrated in vacuo. The resulting solids were purified

by flash chromatography on silica with hexane/ethyl acetate (7:3) to give

pure 4-methyl-6-nitro-3,4-dihydro-2H-benzo[1,4]oxazine (4) (0.031g) in
93% yield. To (4) (2.16g, 11.12 mmol) and 10% palladium on carbon
(0.216g, 10 wt. %) under argon was added methanol (MeOH) (30mL)
followed by THF (30mL). Hydrogen was bubbled thru the resulting slurry

5   until no (4) remained visible by thin layer chromatography (2h). Celite was
added and the mixture was filtered through a bed of celite followed by a
MeOH wash. The resulting solution was concentrated in vacuo to give
pure 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylamine (5) (1.86g) as a
pale purple oil in 100% yield which was carried on without further

10 purification. To (5) (1.86g, 11.34 mmol) and imidazoline-2-sulfonic acid
(1.84g, 12.24 mmol) in anhydrous acetonitrile (50mL) under argon at 0°C
was added triethylamine (3.26mL, 23.36 mmol). This solution was
gradually warmed to ambient temperature and stirred for 16h. At that
time an additional amount of imidazoline-2-sulfonic acid (0.86g, 5.55

15 mmol) was added and the resulting mixture was stirred an additional 5h.
This solution was concentrated in vacuo and the residues were taken up in
H_2O. The organics were extracted into CH_2Cl_2 and washed twice with
- NaOH and then brine, dried over $MgSO_4$ and concentrated in vacuo. The
resulting foam was purified by flash chromatography on silica with 20%

20 methanol (saturated with ammonia) in chloroform to give pure
imidazolidin-2-ylidene-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-
yl)amine (6) (E-1) (0.905g) in 34% yield.

^{1}H NMR (CDCl3): 2.81 (s, 3H); 3.26 (t, J=8.9 Hz, 2H); 3.60 (s, 4H); 4.26 (m,
2H); 4.60 (vbrs, 2H); 6.34 (dd, J=8.2 Hz, J=2.4 Hz, 1H); 6.39 (d, J=2.4 Hz,

25 1H); 6.68 (d, J= 8.2 Hz, 1H).

Example F & G

Procedure for Preparation of 6-(imidazolidin-2-ylidene amino)-5-methyl-4H-benzo[1,4]oxazin-3-one (F) and Imidazolidin-2-ylidene-(5-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl)amine (G):

31

Procedure -

To 2-amino-3-methylphenol (1) (14.72g, 0.120 mol), triethylamine

(35.0mL, 0.251 mol) and 4-dimethylaminopyridine (0.29g, 2.39 mmol) in

anhydrous CH_2Cl_2 (100mL) at $0°C$ under argon was added chloroacetyl

5   chloride (10.0mL, 0.126 mol) dropwise via syringe. After the addition was

complete the resulting solution was refluxed for 24h. The organics were

washed successively with phosphoric acid (0.5M), saturated sodium

bicarbonate, water and brine and then dried over $MgSO_4$. The resulting

solution was concentrated and taken up in THF to which ether was added.

10   The resulting crystals were filtered off to give pure 5-methyl-4H-

benzo[1,4]oxazin-3-one (2) (12.30g) in 63% yield. To (2) (14.64g, 89.72

mmol) dissolved in concentrated H_2SO_4 (65 mL) at $-10°C$ was added 70%

concentrated HNO_3 (8.08g, 89.72 mmol) in concentrated H_2SO_4 (25mL) with

rapid mechanical stirring at a rate whereby the internal temperature was

15   maintained below $-5°C$. As soon as the addition was complete the mixture

was poured onto crushed ice (500mL) and the resultant solids were filtered

off and slurried in cold water (300 mL) while sufficient NaOH was added

to adjust the pH to 7. The recovered yellow powder was dissolved in THF,

adhered to silica and purified by flash chromatography with 60% hexane

20   and ethyl acetate to give the nitrated product as a mixture of two

regioisomers, i.e. the desired 6-substituted aromatic comprising 6-nitro-5-

methyl-4H-benzo[1,4]oxazin-3-one (3) (55%) and the 8-substituted by-

product comprising 8-nitro-5-methyl-4H-benzo[1,4]oxazin-3-one (4) (22%).

These isomers are separated with difficulty at this point and were carried

25   on to the next step as a mixture. To a mixture of (3) (1.93 g, 9.27mmol) and

(4) (0.48g, 2.32 mmol) dissolved in a solution of MeOH (300mL) and THF

32

(300mL) under argon was added 10% palladium on carbon (1.20g). The resulting solution was subjected to H$_2$ at one atmosphere pressure. After 16h the catalyst was filtered off and the resulting solution was concentrated in vacuo and purified by flash chromatography on silica with 50% hexane

5   and ethyl acetate to give 6-amino-5-methyl-4H-benzo[1,4]oxazin-3-one (5) (0.96 g) in 46% yield and 8-amino-5-methyl-4H-benzo[1,4]oxazin-3-one (6) (0.17 g) in 8% yield. (5) (1.20g, 6.74 mmol), imidazoline-2-sulfonic acid (2.02g, 13.48 mmol) and triethylamine (2.35mL, 16.85 mmol) were heated at reflux in anhydrous acetonitrile (50mL) under argon for 48h. At that time

10   an additional amount of imidazoline-2-sulfonic acid (1.01g, 6.74 mmol) and triethylamine (1.41mL, 10.12 mmol) were added and the resulting mixture was stirred an additional 24h. This solution was concentrated in vacuo and the residues were taken up in a solution of CHCl$_3$/isopropyl alcohol (3:1) and washed successively with NaOH (1N) and brine, dried over MgSO$_4$

15   and concentrated in vacuo. The resulting foam was purified by flash chromatography on silica with 20% methanol saturated with ammonia in chloroform to give 6-(imidazolidin-2-ylideneamino)-5-methyl-4H-benzo[1,4]oxazin-3-one (7) (0.42g) as a foam in 27% yield along with 55% recovered starting material. The HCl salt was recrystallized from a mixture

20   of ethanol and diethyl ether (EtOH/Et$_2$O) to give fine white needles.

^{1}H NMR (DMSO): 2.10 (s, 3H); 3.59 (s, 4H); 4.53 (s, 2H); 6.83 (d, J=8.6 Hz, 1H); 6.90 (d, J= 8.6 Hz, 1H); 8.07 (brs, 2H); 10.15 (vbrs, 1H); 10.42 (s, 1H).


(6) (0.222 g, 1.35mmol), imidazoline-2-sulfonic acid (0.223 g, 1.49mmol) and

25   triethylamine (0.415 mL, 2.98mmol) were heated at 95°C in anhydrous acetonitrile (10 mL) in a sealed tube for 2h. At that time an additional

33

amount of imidazoline-2-sulfonic acid (0.112 g, 0.75mmol) was added and
the reaction was continued for an additional 16 h. This solution was
concentrated in vacuo and the residues were taken up in a solution of
CHCl$_3$/isopropyl alcohol (3:1) and washed successively with NaOH (2N)

5   and brine, dried (MgSO$_4$) and concentrated in vacuo. The resulting oil was
recrystalizied from CHCl$_3$ to give pure 6-(imidazolidin-2-ylideneamino)-5-
methyl-4H-benzo[1,4]oxazin-3-one (8) (F) (0.048 g) as a white powder in
15% yield along with 35% recovered starting material. To a slurry of (8),
(0.08 g, 0.321mmol) in anhydrous THF (50 mL) under argon in a 3-neck

10   round-bottom flask equipped with reflux condenser was added borane-
dimethyl sulfide complex (0.48 mL, 0.936mmol). The mixture was heated
at reflux until starting material was no longer observed via thin layer
chromatography (3 h). The reaction mixture was cooled to room temp-
erature and carefully quenched by the dropwise addition of methanol. The

15   crude reaction mixture was concentrated in vacuo and purified by flash
chromatography on silica using 20% methanol saturated with ammonia/
chloroform to give imidazolidin-2-ylidene-(5-methyl-3,4-dihydro-2H-
benzo[1,4]oxazin-8-yl)amine (9) (G) (0.03 g) as the HCl salt in 37% yield.

^{1}H NMR (CDCl3): 2.07 (s, 3H); 3.46 (t, J=4.3Hz, 2H); 3.55 (s, 4H); 4.24 (t,

20   J=4.3Hz, 2H); 5.60 to 5.95 (vbrs, 2H); 6.44 (d, J=8.0 Hz, 1H); 6.57 (d, J=8.0 Hz,
1H).

Example H
Procedure for Preparation of 4(5)-phenylsulfanyl-1H-imidazole :

34

Procedure -

1-(N,N-dimethylsulfamoyl)imidazole (1.5g, 8.6 mmol) was taken up in 28mL of THF. The solution was cooled to -78°C and n-BuLi (5.4mL, 8.6

5   mmol) added dropwise via syringe. After stirring at -78°C for 1h TBSCl (1.3g, 8.56 mmol) in 10mL of THF was added. The bath was removed and the reaction allowed to warm-up to rt. The reaction mixture was stirred overnight. The reaction mixture was cooled to -20°C and n-BuLi (5.4 mL, 8.6 mmol) added. After 45 min phenyldisulfide (1.9g, 8.6 mmol) in 8mL of

10   THF was added. The reaction mixture was stirred at rt for 48h. The reaction mixture was quenched with saturated ammonium chloride and extracted with ethyl acetate. The organic layer was collected and washed with water and then brine. The solution was dried over sodium sulfate and the solvent removed under reduced pressure. Flash chromatography

15   (2.5% EtOAc/hexane) afforded 2.8g (7.0 mmol) of 2-(t-butyldimethylsilyl)-5-phenylsulfanylimidazole-1-sulfonic acid dimethylamide (1) as a yellow color oil. The compound (1) (2.8g, 7.0 mmol) was dissolved in THF and the solution cooled to 0°C. TBAF (7.0mL, 7.0 mmol) was added dropwise to the solution. The reaction mixture was stirred overnight at rt. The next

20   day the reaction was quenched with water and extracted with ethyl acetate.

The organic layer was washed with water followed by brine. The solution
was dried over sodium sulfate and the solvent removed under reduced
pressure. Flash chromatography (50% EtOAc/hexane) afforded 474mg of
5-phenylsulfanylimidazole-1-sulfonic acid dimethylamide (2) and 290mg of

5   5-phenylsulfanyl-1H-imidazole (3) (H). The 478mg of (2) was added to 2N
     HCl and the solution heated at reflux for 2h. The reaction mixture was
     made basic with 2N NaOH and extracted with ethyl acetate. The organic
     layer was washed with water followed by brine. The solution was dried
     over sodium sulfate and the solvent removed under reduced pressure.

10   Flash chromatography (EtOAc) afforded (3) as a white crystalline solid. A
     combined total of 360mg (2.0 mmol) of (3) is recovered.
   ¹H NMR (300 MHz, CD₃OD) 7.91 (s, 1H), 7.37 (s, 1H), 7.19-7.23 (m, 2H),
     7.07-7.11 (m, 3H).

15   Example I
     Procedure for Preparation of 4(5)-(1,2,3,4-tetrahydronaphthalen-2-
     ylmethyl)-4,5-dihydro-1H-imidazole, methane sulfonic acid salt :

36

Procedure -

To 1,2,3,4-tetrahydronaphthalene-2-carboxylic acid (1) (4.93g, 27.42

mmol in anhydrous THF (250mL) at 20°C under argon was added 3.26 mL

(32.90 mmol) borane-dimethylsulfide (BH$_3$-Me$_2$S) via syringe. After

stirring for 16h MeOH (4mL) was added and the mixture was warmed to

55°C until no more gas was evolved. The mixture was concentrated to an

37

oil, taken up in Et_2O and washed successively with 2M phosphoric acid,

saturated sodium bicarbonate, water and brine and then dried over $MgSO_4$

and reconcentrated. The resulting oil was purified by high vacuum

Kugelrohr at 150°C to give pure alcohol (1,2,3,4-tetrahydronaphthalen-2-

5   yl)methanol (2) (4.09g) in 93% yield. To triphenylphosphine (10.179g,

38.809 mmol) and imidazole (2.64g, 38.809 mmol) in anhydrous benzene

(175mL) was added the iodine (8.60g, 33.865 mmol) in benzene (75mL)

with rapid stirring followed by (2) in benzene (50mL). After 3h the solids

were filtered off and the filtrate was reduced in vacuo to a volume of 50mL

10   to which was added hexane (200mL). The resultant solids were filtered off

and the filtrate was washed successively with water and brine, dried over

$MgSO_4$ and concentrated in vacuo. The resulting oil was purified by flash

chromatography on silica with hexane to give pure 2-iodomethyl-1,2,3,4-

tetrahydronaphthalene (3) (6.239g) in 90% yield. To (3) (10.02 g, 36.85

15   mmol) and CuI (1.41g, 7.37 mmol) in anhydrous THF (50mL) at -78°C

under argon was added vinylmagnesium bromide (1M in THF, 73.70mL,

73.70 mmol) slowly at a speed at which no color developed. This solution

was allowed to warm to 0°C and stirred for 6h. The resulting mixture was

recooled to -40°C and quenched by the careful addition of 2M phosphoric

20   acid (35mL). This solution was diluted with 100mL water and extracted

with hexanes. The organic fractions were washed successively with water

and brine, dried over $MgSO_4$ and concentrated in vacuo. The resulting oil

was purified by flash chromatography on silica with hexane to give 2-allyl-

1,2,3,4-tetrahydronaphthalene (4) (5.618g) in 88% yield. (4) (5.615g, 32.645

25   mmol) and meta-chloroperbenzoic acid (m-CPBA) (14.08g, 81.613 mmol)

were stirred in anhydrous methylene chloride (50mL) for 16h. The solids

38

were filtered off and potassium flouride KF (5.11g, 88.142 mmol) was
added and this mixture was stirred an additional hour. The solids were
filtered off and the reaction was concentrated in vacuo. The resulting oil
was purified by flash chromatography on silica with 5% ethyl acetate in

5   hexane to give 2-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)oxirane (5)
       (5.41g) in 88% yield. To (5) (1.626g, 8.649 mmol) in a solution of acetone
       (20mL) and water (5mL) was added sodium azide (1.97g, 30.271 mmol).
       This solution was warmed to 85°C and stirred for 48h. The solution was
       concentrated in vacuo and the residues were taken up in $CHCl_3$ and

10   washed successively with water and brine, dried over $MgSO_4$ and
       concentrated in vacuo. The resulting oil was purified by flash
       chromatography on silica with 30% ethyl acetate in hexane to give pure 1-
       azido-3-(1,2,3,4-tetrahydronaphthalen-2-yl)propan-2-ol (6) (1.762g) in 88%
       yield. A mixture of (6) (1.88g, 8.140 mmol), triphenylphosphine (2.67g,

15   10.173 mmol), phthalimide (1.50g, 10.173 mmol), diethyl azodicarboxylate
       (DEAD) (1.77g, 10.173 mmol) were stirred in anhydrous THF (50mL) for
       4h. This solution was concentrated in vacuo, taken up in a solution of
       hexane (25mL) and ether (25mL) and stirred for 16h. The solids were
       filtered off and the filtrate was concentrated in vacuo. The resulting oil was

20   purified by flash chromatography on silica with 20% ethyl acetate in
       hexane to give 2-[1-azidomethyl-2-(1,2,3,4-tetrahydronaphthalen-2-
       yl)ethyl]isoindole-1,3-dione (7) (2.487g) contaminated with a small amount
       of impurity which was carried on without further purification. A mixture
       of (7) (3.93g, 10.917 mmol) and hydrazine (0.680mL, 21.833 mmol) were

25   heated in ethanol (60mL) at reflux for 16h. The solids were filtered off and
       the filtrate was concentrated in vacuo. The residues were purified by flash

39

chromatography on silica with 5% MeOH in CH_2Cl_2 to give 1-azidomethyl-2-(1,2,3,4-tetrahydronaphthalen-2-yl)ethylamine (8) (2.057g) in 88% yield. A mixture of (8) (2.056g, 8.940 mmol) and 10% palladium on carbon (0.260 g) were stirred in MeOH (30mL) under 1 atmosphere of hydrogen for 16h.

5   The solids were filtered off and the filtrate was concentrated in vacuo. The 'residues were purified by flash chromatography on silica with 10% ammonia saturated MeOH in CH_2Cl_2 to give 3-(1,2,3,4-tetrahydro-naphthalen-2-yl)propane-1,2-dione (9) (1.557g) in 85% yield. A mixture of (9) (0.590g, 2.892 mmol) and methanesulfonic acid (0.980mL, 14.460 mmol)

10   were heated in triethylorthoformate (10mL) at 105°C 3h. The reaction was concentrated in vacuo and the solids were filtered off. Subsequent recrystalization of these solids from a mixture of MeOH and ether gave pure 4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole, methane sulfonic acid salt (I) (0.435g) in 48% yield.

15   ^{1}H NMR ($CDCl_3$): 1.37 to 1.56 (m, 1H); 1.56 to 1.70 (m, 1H); 1.80 to 2.02 (m, 2H); 2.32 to 2.55 (m, 2H); 2.72 (s, 3H); 2.75 to 2.95 (m, 3H); 3.48 to 3.59 (m, 1H); 3.93 to 4.08 (m, 1H); 4.31 to 4.47 (m, 1H); 7.00 to 7.20 (m, 4H); 8.46 (s, 1H); 10.04 (s, 1H); 10.35 (brs, 1H).

20   Example J-1

Procedure for Preparation of 4(5)-cyclohexylmethyl-1H-imidazole :

25

Procedure -

2-Tert-butyldimethylsilyl-1-dimethylsulfamoyl imidazole (1) (4.1g, 14.2 mmol) is taken up in 47 mL of anhydrous THF and cooled to -20°C. n-

5   BuLi (8.9 mL, 14.2 mmol) is added dropwise to the solution of (1). The resultant solution is stirred at -20°C for 45 min. Cyclohexylmethyl iodide (2) (3.14g, 14 mmol) is then added dropwise to the reaction mixture. Then reaction is warmed to rt and stirred overnight. The next day the reaction is quenched with saturated ammonium chloride and diluted with water. The

10   mixture is extracted with ethyl acetate (3 x 100 mL). The organic layers are combined and washed with water followed by brine. The organic phase is dried over sodium sulfate and the solvent removed under reduced pressure. Flash chromatography (4:1 ethyl acetate/ hexane) affords 2.26g (5.6 mmol) of 5-cyclohexylmethyl-2-tert-butyldimethylsilyl-1-

15   dimethylsulfamoyl imidazole (3). (3) (2.26g , 5.6 mmol) is taken up in 56 mL of THF and cooled to 0°C. A 1M solution of TBAF in THF (5.6 mL, 5.6 mmol) is added dropwise to the solution of (3). The reaction is warmed to rt and stirred overnight. The next day the reaction is quenched with water and then extracted with ethyl acetate. The organic layer is washed with

20   water followed by brine. The organic phase is dried over sodium sulfate

41

and the solvent removed under reduced pressure. Flash chromatography (1:1 ethyl acetate/ hexane) affords 1.2g (4.42 mmol) of 5-cyclohexylmethyl - 1-dimethylsulfamoyl imidazole (4). (4) (1.2g, 4.42 mmol) is taken up in 25 mL of a 1.5N HCl solution and heated at reflux for 2h. The reaction is cool

5   to rt and diluted with ethyl acetate. The mixture is brought to pH 13 with 2N NaOH and then extracted with chloroform (4 x 100 mL). The organic layers are combined and washed with water followed by brine. The organic phase is dried over sodium sulfate and the solvent removed under reduced pressure. Flash chromatography (9:1 chloroform/ methanol)

10   affords 700 mg (4.27 mmol) of 4(5)-cyclohexylmethyl-1H-imidazole (5) (J-1).

^{1}H NMR (CDCl$_3$): 0.92 to 1.0 (m, 2H); 1.16 to 1.26 (m, 3H); 1.57 to 1.73 (m, 6H); 2.48 (d, J=6.9 Hz, 2H); 6.77 (s, 1H); 7.56 (s, 1H)

Example J-2

15   (S)-2-iodomethyl-1,2,3,4-tetrahydronaphthalene is substituted into the method of Example J-1 to yield (S)-4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole. (S)-2-iodomethyl-1,2,3,4-tetrahydronaphthalene was prepared from (S)-1,2,3,4-tetrahydro-2-naphthoic acid. (S)-1,2,3,4-tetrahydro-2-naphthoic acid was prepared from the resolution of 1,2,3,4-

20   tetrahydro-2-naphthoic acid (*J. Med. Chem.* 1983, 26, 328-334)

Example J-3

(R)-2-iodomethyl-1,2,3,4-tetrahydronaphthalene is substituted into the method of Example J-1 to yield (R)-4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole. (R)-2-iodomethyl-1,2,3,4-tetrahydronaphthalene

25   was prepared from (R)-1,2,3,4-tetrahydro-2-naphthoic acid. (R)-1,2,3,4-

42

tetrahydro-2-naphthoic acid was prepared from the resolution of 1,2,3,4-tetrahydro-2-naphthoic acid (*J. Med. Chem.* 1983, *26*, 328-334)

Example K-1

5   Procedure for Preparation of 4(5)-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylmethyl)-1H-imidazole :

Procedure -

4,5,6,7-tetrahydrobenzo[b]thiophene (1) (2.1g, 15 mmol) is taken up in 75mL of anhydrous THF and cooled to -78°C. n-BuLi (6.0mL, 15 mmol)
15 is added dropwise to the solution of (1). The resultant solution is stirred at -78°C for 60 min. 1-Dimethylsulfamoyl-2-t-butyldimethylsilyl-5-

43

imidazolecarboxaldehyde (2) (4.8g, 15 mmol) in 25mL of THF is added to the reaction. The reaction is warmed to rt and stirred for 2h before being quenched with water and diluted with ethyl acetate. The organic layer is washed with water followed by brine. The organic phase is dried over

5   sodium sulfate and the solvent removed under reduced pressure. Flash chromatography (1:3 ethyl acetate/ hexane) affords 5.2g (11 mmol) of 2-(tert-butyldimethylsilyl)-5-[hydroxy-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)methyl]imidazole-1-sulfonic acid dimethylamide (3). (3) (5.2g, 11.3 mmol) is taken up in 57mL of THF. A 1M solution of tetra-n-

10   butylammonium fluoride (TBAF) in THF (11.3mL, 11.3 mmol) is added dropwise to the solution of (3). The reaction is stirred for 1h 15min reaction before being quenched with water and then extracted with ethyl acetate. The organic layer is washed with water followed by brine. The organic phase is dried over sodium sulfate and the solvent removed under reduced

15   pressure. Recrystallization from hexane/ethyl acetate affords 5-[hydroxy-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl)methyl]imidazole-1-sulfonic acid dimethylamide (4) (2.1g, 6.2 mmol). An additional 2g of the crude product is also recovered. (4) (2.0g, 5.9 mmol) is taken up in 78mL of dichloromethane, to the solution is added 7.5 mL (46.9 mmol) of

20   triethylsilane and 14.4 mL (0.19 mol) of trifluoroacetic acid. The reaction is stirred at rt overnight and then quenched with water and neutralized with 2N NaOH. The organic layer is washed with water followed by brine. The organic phase is dried over sodium sulfate and the solvent removed under reduced pressure. Flash chromatography using a 1:1 mixture of ethyl

25   acetate and hexane affords 0.75g (2.3 mmol) of 5-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylmethyl)imidazole-1-sulfonic acid

44

dimethylamide (5). (5) (0.42g, 1.55 mmol) is taken up in 15mL of a 1.5N

HCl solution and heated at reflux for 2h and then stirred at rt overnight.

The reaction is diluted with ethyl acetate, neutralized with 2N NaOH. The

organic layer is washed with water followed by brine. The organic phase

5   is dried over sodium sulfate and the solvent removed under reduced

' pressure. The crude product is dissolved in methanol and an excess of HCl

in ether is added. Solvent is removed under reduced pressure to afford

0.6g (2.3 mmol) of 4(5)-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylmethyl)-

1H-imidazole (6) (K-1).

10   ^{1}H NMR (CD$_3$OD): 8.80 (s, 1H); 7.34 (s, 1H); 6.57 (s, 1H); 4.18 (s, 2H); 2.65

to 2.69 (m, 2H); 2.51 to 2.55 (m, 2H); 1.74 to 1.83 (m, 4H)

Example K-2

2-(Tert-butyl) furan is substituted into the method of Example K-1 to yield 4(5)-(5-tert-butylfuran-2-ylmethyl)-1H-imidazole

15   ,   ### Example K-3

5,6-Dihydro-4H-thieno[2,3-b]thiopyran is substituted into the method of

Example K-1 to yield 4(5)-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-

ylmethyl)-1H-imidazole

Example L

20   Procedure for Preparation of 4(5)-(1-furan-2-ylethyl)-1H-imidazole:

45

1) n-BuLi

2)

TBAF

1

3

MnO₂

MeMgCl

4

5

Et₃SiH

CF₃CO₂H
CH₂Cl₂

1.5 N HCl

reflux

6

7

8

Procedure -

2-(Tert-butyldimethylsilyl)-1-(dimethylsulfamoyl)imidazole (1) (3.3

g, 11.4 mmol) is taken up in 38mL of anhydrous THF and cooled to -78°C.

n-BuLi (7.2mL, 11.4 mmol) is added dropwise to the solution of (1). The

resultant solution is stirred at -78°C for 30 min. 2-Furfural (2) (0.94mL, 11.4

mmol) is added to the reaction. The reaction is warmed to rt and stirred

overnight. The next day the reaction is quenched with saturated
ammonium chloride and diluted with ethyl acetate. The organic layer is
washed with water followed by brine. The organic phase is dried over
sodium sulfate and the solvent removed under reduced pressure. Flash

5   chromatography (4:1 ethyl acetate/ hexane) affords 4.4g (11.4 mmol) of 2-
'(t-butyldimethylsilyl)-5-(furan-2-ylhydroxy-methyl)imidazole-1-sulfonic
acid dimethylamide (3). (3) (4.4g, 11.4 mmol) is taken up in 110mL of THF
and cool to 0°C. A 1M solution of tetra-n-butylammonium fluoride (TBAF)
in THF (11.4mL, 11.4 mmol) is added dropwise to the solution of (3). The

10 reaction is stirred overnight at rt. The next day the reaction is quenched
with water and then extracted with ethyl acetate. The organic layer is
washed with water followed by brine. The organic phase is dried over
sodium sulfate and the solvent removed under reduced pressure. 3.9g of
crude 5-(furan-2-ylhydroxymethyl)imidazole-1-sulfonic acid

15 dimethylamide (4) is recovered. (4) (1.0g, 3.7 mmol) is taken up in 37mL
of dichloromethane, to the solution is added 1.6g (18.5 mmol) of
manganese dioxide. The reaction is stirred at rt overnight and then filtered
through celite. The eluent is collected and the solvent removed under
reduced pressure. Flash chromatography using a 1:1 mixture of ethyl

20 acetate and hexane affords 0.69g (2.6 mmol) of 5-(furan-2-
ylcarbonyl)imidazole-1-sulfonic acid dimethylamide (5). (5) (0.69g, 2.6
mmol) is taken up in 26mL of THF. The solution is cool to -78°C. 1.7mL
(5.1 mmol) of a 3M solution of methylmagnesium chloride is added. After
stirring at -78° C for 1.5h reaction is warmed to rt and stirred for an

25 additional hour. The reaction is quenched with water and then extracted
with ethyl acetate. The organic layer is washed with water followed by

47

brine. The organic phase is dried over sodium sulfate and the solvent
removed under reduced pressure. Crystallization from ether/hexane
affords 0.39g (1.4 mmol) of 5-(1-furan-2-yl-1-hydroxyethyl)imidazole-1-
sulfonic acid dimethylamide (6). An additional 0.19g of (6) is recovered.

5   (6) (0.58g, 2.0 mmol) is taken up in 27mL of dichloromethane, to the
       solution is added 2.6 mL (16.3 mmol) of triethylsilane and 5.5 mL (71.4
       mmol) of trifluoroacetic acid. The reaction is stirred at rt overnight and
       then quenched with water and neutralized with solid sodium bicarbonate.
       The organic layer is washed with water followed by brine. The organic

10   phase is dried over sodium sulfate and the solvent removed under reduced
       pressure.
       Flash chromatography using a 2:1 mixture of ethyl acetate and hexane
       affords 0.53g (2.0 mmol) of 5-(1-furan-2-ylethyl)imidazole-1-sulfonic acid
       dimethylamide (7). (7) (0.34g, 1.3 mmol) is taken up in 10mL of a 1.5N HCl

15   solution and heated at reflux for 30min and then stirred at rt overnight.
       The reaction is diluted with ethyl acetate and then made basic with 2N
       NaOH. The organic layer is washed with water followed by brine. The
       organic phase is dried over sodium sulfate and the solvent removed under
   reduced pressure. Flash chromatography (10:1 chloroform/methanol)

20   affords 0.1g (0.62 mmol) of 4(5)-(1-furan-2-ylethyl)-1H-imidazole (8) (L).

       ^{1}H NMR (300 MHz, CDCl$_3$) 7.56 (m, 1H), 7.33-7.34 (m, 1H), 6.81 (m, 1H),
       6.29-6.31 (m,1H), 6.06-6.07 (m,1H), 4.22 (q, J= 7.2 Hz, 1H), 1.63 (d, J= 7.2
       Hz, 3H).

25

48

Example M

Procedure for Preparation of 4(5)-(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-4-methyl-1H-imidazole :

1

2

3

4

5

6

5

Procedure -

4-Methyl-1-(dimethylsulfamoyl)imidazole (1) (2.0g, 10.6 mmol) is taken up in 42mL of anhydrous THF and cooled to -78°C. n-BuLi (6.6mL, 10.6

10   mmol) is added dropwise to the solution of (1). The resultant solution is stirred at -78°C for 30 min. Tert-butyldimethylsilylchloride (TBSCl) (1.6g, 10.6 mmol) in 10mL of THF is added to the reaction. The reaction is warmed to rt and stirred overnight. The next day the reaction is cooled to -20°C and 7.3mL (11.6 mmol) of n- BuLi added. After stirring at -20°C for 30

15   min, 1,4-benzodioxan-6-carboxaldehyde (2) (1.92g, 11.7 mmol) in 10mL of

THF is added to the reaction mixture. Then reaction is warmed to rt and
stirred for 3h. The reaction is quenched with water and diluted with ethyl
acetate. The organic layer is washed with water followed by brine. The
organic phase is dried over sodium sulfate and the solvent removed under
5   reduced pressure. Flash chromatography (1:2 ethyl acetate/ hexane)
affords 3.9g (8.4 mmol) of 2-(t-butyldimethylsilyl)-5-[(2,3-dihydro
benzo[1,4]dioxin-6-yl)hydroxymethyl]-4-methylimidazole-1-sulfonic acid
dimethylamide (3). (3) (1.0g, 2.14 mmol) is taken up in 21mL of THF. A
1M solution of tetra-n-butylammonium fluoride (TBAF) in THF (2.35mL,
10   2.35 mmol) is added dropwise to the solution of (3). The reaction is stirred
for 30min at rt. The reaction is quenched with water and then extracted
with ethyl acetate. The organic layer is washed with water followed by
brine. The organic phase is dried over sodium sulfate and the solvent
removed under reduced pressure. Flash chromatography using ethyl
15   acetate as eluant affords 0.75g (2.12 mmol) 5-[(2,3-
dihydrobenzo[1,4]dioxin-6-yl)hydroxymethyl]-4-methylimidazole-1-
sulfonic acid dimethylamide (4). (4) (0.75g, 2.12 mmol) is taken up in
28mL of dichloromethane, to the solution is added 2.7mL (17.0 mmol) of
triethylsilane and 5.2mL (67.8 mmol) of trifluoroacetic acid. The reaction is
20   stirred at rt overnight and then quenched with water and neutralized with
solid sodium bicarbonate. The organic layer is washed with water followed
by brine. The organic phase is dried over sodium sulfate and the solvent
removed under reduced pressure. Flash chromatography using a 3:1
mixture of ethyl acetate and hexane affords 0.63g (1.87 mmol) of 5-(2,3-
25   dihydrobenzo[1,4]dioxin-6-ylmethyl)-4-methylimidazole-1-sulfonic acid
dimethylamide (5). (5) (0.63g, 1.87 mmol) is taken up in 10mL of a 1.5N

50

HCl solution and heated at reflux for. The reaction is diluted with ethyl acetate, neutralized with solid sodium bicarbonate. The organic layer is washed with water followed by brine. The organic phase is dried over sodium sulfate and the solvent removed under reduced pressure.

5   Crystallization from ether/hexane affords 0.33g (1.43 mmol) of 4(5)-(2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl)-4-methyl-1H-imidazole (6) (M).

^{1}H NMR (300 MHz, acetone-d^6) 7.37 (s, 1H), 6.66-6.67 (m, 3H), 4.18 (s, 4H), 3.73 (s,1H), 2.13 (s, 3H)

10   Example N

Procedure for Preparation of 2-(3H-imidazol-4(5)-ylmethyl)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one (N-1), 4(5)-(2,3,4,4a,5,6,7,8-octahydronaphthlen-2-ylmethyl)-1H-imidazole (N-2) and 4(5)--(1,2,3,4,5,6,7,8-octahydronaphthalen-2-ylmethyl)-1H-imidazole (N-3):

15

Procedure :

1-Decalone (10.0g, 66 mmol) and 4(5)-imidazole carboxaldehyde (6.3g, 66 mmol) were added to 100 mL of ethanol. To the solution was

added NaOH (5.2g, 130 mmol) in 20 mL of water. The reaction was heated

at reflux for 5 days. The reaction was cooled to rt and made basic with

aqueous HCl. The solution was extracted with THF/ethyl acetate. The

organic layers were combined and washed with brine. The organic phase

5   was dried over magnesium sulfate and the solvent removed under reduced

pressure to afford the crude product. The crude product was heated at

reflux in 40% H_2SO_4 for 1 day. The reaction was cooled to rt and made

basic with saturated K_2CO_3. The solution was extracted with THF/ethyl

acetate. The organic layers were combined and washed with brine. The

10   organic phase was dried over magnesium sulfate and the solvent removed

under reduced pressure. Purification by flash chromatography (15:1

CH_3Cl/MeOH) afforded N-1 (4.9g, 32% yield).

^{1}H NMR : 7.55 (s,1H), 6.77 (s, 1H), 3.08-3.14 (m, 2H), 1.52-2.46 (m, 13H).

The free base of the hydrochloride salt of N-1 (3.0g, 11 mmol) was

15   generated with NaOH and then added to diethylene glycol (100mL). To

the solution was added hydrazine hydrate (3.2 mL, 100 mmol) and the

reaction was left to stir overnight at rt. NaOH (3.1g, 77 mmol) was added

and the solution heated at reflux for 5 days. The reaction was cooled to rt

and diluted with water. The solution was extracted with THF/ethyl

20   acetate. The organic layers were combined and washed with brine. The

organic phase was dried over magnesium sulfate and the solvent removed

under reduced pressure. Purification by flash chromatography (8:1

CH_3Cl/MeOH) afforded N-2 (0.64g, 27% yield).

^{1}H NMR : 7.58 (s,1H), 6.76 (s, 1H), 5.24 (d, J= 4.3 Hz, 1H), 0.91-2.58 (m,

25   16H).

52

N-2 (1.0g, 4.6 mmol) was added to 10 mL of concentrated HCl. The

solution was stirred at rt for 30 min and then neutralized with K_2CO_3. The

solution was extracted with THF/ethyl acetate. The organic layers were

combined and washed with brine. The organic phase was dried over

5   magnesium sulfate and the solvent removed under reduced pressure.

·Purification by flash chromatography (15:1 $CH_3Cl/MeOH$) afforded N-3.

^1H NMR : 7.54 (s,1H), 6.74 (s, 1H), 2.45-2.52 (m, 3H), 1.46-1.97 (m, 14H).

Example O

10   Procedure for Preparation of 4(5)-octahydro pentalen-2-ylmethyl)-1H-

imidazole, hydrochloride:

15

20

25

53

Procedure-

A.   Following the synthesis of White and Whitesell, *Synthesis* pp. 602-3 (1975), ether (10 mL) was added to a flame-dried flask cooled to 0°C and then kept under an argon atmosphere. Then n-butyl lithium (35 mL of 2.5

5   M solution in hexane, 2.2 equiv.) was added and subsequently diisopropyl amine (14 mL, 2.5 equiv.) was added slowly and the mixture was allowed to stir for 30 min. at 0°C. To this generated solution of lithium diisopropyl amide was added cyclooctene oxide (5.0 g, 1.0 equiv.). The mixture was stirred at rt for one day and then heated to reflux under argon atmosphere

10   for 2 days. The reaction was quenched by addition of NH_4Cl. The solution was extracted with THF/EtOAc. The organic extracts were combined, washed with brine, dried over magnesium sulfate and concentrated in vacuo to afford a yellow brown oil which was the 1-hydroxy-octahydropentalene. The compound was used without further purification

15   in the next step.

B.   The alcohol thus obtained (5.0 g, 1 equiv.) was dissolved in dichloromethane (200 mL) and to this solution was added pyridinium chlorochromate (13 g, 1.5 equiv.) and the mixture was stirred at rt for one day. The solution was then filtered through a short column of SiO_2 using

20   diethyl ether as eluent. The obtained solution was concentrated in vacuo to afford a pale green-yellow oil which was used without further purification in the next step.

C.   The octahydro-pentalen-1-one (5.0 g, 1.0 equiv.) of the above step was added to 4(5)-imidazolecarboxaldehyde (3.8 g, 1.0 equiv.) and 40%

25   H_2SO_4 (20 ml) and the mixture was maintained at 90°C for 3 days. The reaction was then quenched by addition of ammonium hydroxide and

54

extracted with tetrahydrofuran/ethyl acetate. The organic extracts were combined, washed with brine, dried over magnesium sulfate. The resulting aqueous layer was neutralized with HCl/ NH₄Cl. The aqueous layer was re-extracted as above and the combined organic fractions were

5   concentrated in vacuo to afford an orange solid.

D.   This orange solid was dissolved in ethanol to which palladium on carbon (0.5 g) was added. The reaction flask was placed under 40 psi of hydrogen for one day. The reaction solution was filtered though celite with more ethanol used as eluent. The solution was concentrated in vacuo

10   to afford a yellow brown oil. Purification by column chromatography using 17:1 chloroform/methanol afforded the ketone product in a somewhat impure state.

E.   The ketone functionality was then removed by addition of the product of the step above (8.2 g, 1.0 equiv.) to diethylene glycol (80 mL)and

15   hydrazine hydrate (13.0 g, 1.0 equiv.). This mixture was stirred overnight and then potassium hydroxide (11.0 g, 5.0 equiv.) was added and the solution was heated under reflux for one day. The reaction solution was cooled to rt and washed with water. The solution was extracted with THF/EtOAc and the combined fractions were washed with brine, dried

20   over magnesium sulfate and concentrated in vacuo to afford a yellow oil. The monohyrdochloride salt was made by dissolving this oil in anhydrous ethanol saturated with HCl and heating.

Example P

25   Procedure for the preparation of 7-(3H-imidazol-4(5)-ylmethyl)-6,7-dihydro-5H-isoquinolin-8-one (P-1) and 7-(3H-imidazol-4(5)-ylmethyl)-5, 6, 7, 8-tetrahydroisoquinoline (P-2)

55

P-1   P-2

Procedure:

A. 3,4-lutidine (21.4g, 1 equiv.) was dissolved in 200 mL of water at 20°C and

potassium permanganate was added in 6.32g portions twice daily for 5 days (total

63.2g, 2 equiv.). After 5 days the solution was stored in the freezer, then thawed

and filtered through celite. The resulting colorless solution was concentrated at

56

90°C on a rotary evaporator until a white solid was obtained. This solid was recrystallized from 5N HCl to give 9.56g of white crystals. NMR indicated a mixture of two regioisomers with the desired isomer being the major product.

B.   These crystals were heated in anhydrous ethanol saturated with HCl gas under argon and at reflux for 6 h. Then ethanol was removed from the solution by rotary evaporation and the residue was taken up in 100 mL of water and the pH was adjusted to between 7 and 8 with solid sodium bicarbonate. The aqueous phase was extracted with diethyl ether (3X) and the combined organic fractions were washed with brine, dried over magnesium sulfate and then filtered and concentrated to give a colorless oil (3.56g., 10.8% yield).

C.   Diisopropylamine 2.84g, 1.3 equiv.) was added to n-BuLi (11.21 mL, 1.3 equiv.) in 100 mL of anhydrous THF under argon at −78°C via syringe to produce lithium diisopropylamide in situ. To this solution was added the product of B above (3.56g, 1 equiv.) in 20 mL of tetrahydrofuran, via syringe and the mixture was stirred at −78°C for 20 min. At this point methyl acrylate (4.85 mL 2.5 equiv.) in 20 mL of tetrahydrofuran was added dropwise through a cannula. The solution was stirred another 2 h before quenching by addition of 40 mL of 10% potassium acetate. The solution was allowed to warm to 20°C and then was concentrated on a rotary evaporator. The aqueous residue was extracted three times with chloroform. The combined fractions were washed with brine and dried over magnesium sulfate, filtered and concentrated to a black solid, which was stored under high vacuum. Chromatography on silica gel with hexanes / ethyl acetate (7/3 → 6/4) afforded 2.41g (58.2%) of the desired product which was used without further purification in the next step.

D.   The material from Step C (0.48g, 1 equiv.) was dissolved in 1 mL of 6M HCl and heated at 105°C for 16 h after which time the solution was concentrated to a solid by rotary evaporation at 80°C. The residue was taken up in 2 mL of water and neutralized with solid sodium bicarbonate. The neutralized solution was extracted

57

with chloroform (3X) and the combined fractions were washed with brine, dried over magnesium sulfate and concentrated to a colorless oil. (0.456g 93.4%).

E. The isoquinolone (1.91 g, 1 equiv.) obtained in step D above was heated with 4(5)-imidazolecarboxaldehyde 1.25g, 1. equiv.) at 110°C in 15 mL of 40% sulfuric .

5   acid for 30 h. The reaction mixture was stored for several days at 0° C under argon. The solution was then diluted with 20 mL of water and basified to pH 8.9 with NH$_4$OH. Solids were collected by filtration and dried with high vacuum. The product was a yellow solid (2.81g, 96.1%) comprising a mixture of both positional isomers at the exo double bond.

10   F. The product of E, above, was dissolved in 150 mL of methanol and to this solution Pd/C (.412g, 0.15 wt. equiv.) was added. The methanolic solution was then saturated with H$_2$ by repeated evacuations and H$_2$ back-fill iterations. The solution was stirred under 1 atm. pressure of H$_2$ for 20 h until TLC revealed that no unsaturated starting material remained. The solution was filtered through celite and

15   concentrated to an oil. Chromatography on silica using dichloromethane and methanol (9/1) recovered pure product (1.853g 6504 %) as a white foam. This was taken up in methanol to which fumaric acid (0.4817g, 1.5 equiv.) was added with warming to dissolve the solids. The solution was cooled slowly and off-white crystals (0.826g, 74%) were obtained, which are represented as the compound P-1.

20   P-2 was obtained by hydrazine reduction in the same manner as described in Step E of Example O above.

Example Q

Procedure for the preparation of (Z)-6-(3H-imidazol-4(5)-ylmethylene)-7,8-
25   dihydro-6H-quinolin-5-one (Q-1), (E)-6-(3H-imidazol-4(5)-ylmethylene)-7,8-dihydro-6H-quinolin-5-one (Q-2), 6-(3H-imidazol-4(5)-ylmethyl)-7,8-dihydro-6H-quinolin-5-one (Q-3), 6-(3H-imidazol-4(5)-ylmethyl)-5,6,7,8-tetrahydroquinoline, dihydrochloride (Q-4) and 6-(3H-imidazol-4(5)-ylmethyl)-octahydroquinolin-5-one (Q-5)

58

Procedure:

A.   The reactive azido reagent of the first step was generated in situ by addition
of iodine monochloride (67.6 g, 1.15 equiv.) in 50 mL of acetonitrile dropwise
through a dropping funnel to a stirred slurry of sodium azide (58.84 g, 2.5 equiv.)

5   in 350 mL of anhydrous acetonitrile at −10°C and under argon. Addition was
complete in 30 min, the mixture was stirred an additional 30 min and
cyclohexenone (34.81 g, 1.0 equiv.) was added via a syringe and then stirred at
20°C for an additional 20 h. The mixture was then poured into a liter of water and
extracted with three 200 mL portions of diethyl ether. The combined fractions were

10   washed with 5% sodium thiosulfate solution and then brine. The organic phase was
dried over magnesium sulfate, filtered and concentrated in vacuo at 20°C. The
residues were taken up in 1 L of DMSO at 0°C and a second portion of NaN_3 was
added and the mixture stirred while warming to ambient temperature. This mixture
was then diluted with 2.5 L of ice water and extracted ten times with dichloro-

15   methane (10 X 250 mL). The combined organic fractions were concentrated on a
rotovap to a volume of ~1 L and this concentrate was extracted three times with
250 mL of water, and then brine, and then dried over magnesium sulfate and
concentrated to a dark oil (39.5 g) and stored at −40°C.
The oil was purified by chromatography on silica using 9/1 to 8/2 hexane:ethyl

20   acetate. Two isomers were recovered, the first with the azido group α to the ketone
function was obtained in 13.22 g, 26.6%, yield. The β-isomer was obtained in
15.825 g, 32.0%, yield.

B.   Triphenyl phosphine was dissolved in 20 mL of dichloromethane and
placed under an argon atmosphere at 20 °C. The β-isomer obtained as described

25   above was added via cannual to the stirred solution and maintained at 20°C for 2 h.
As the reaction progressed nitrogen was liberated from the solution, and after 2 h
TLC demonstrated there was no starting material remaining. The solution was
concentrated and passed through a silica gel column with dichloromethane

60

progressing to 95/5 dichloromethane:methanol as eluent. The amidophosphonate
intermediate was obtained in 2.139 g, 65.1%, yield.

C.   The amidophosphonate was dissolved in 100 mL of anhydrous o-xylene
and then 10% Pd / C was added with stirring. Freshly distilled acrolein was then
5   added to the mixture via syringe and heated to reflux for 4 h, after which time the
remaining acrolein was added and heating under reflux was continued for 44 h
under a finger condenser and under argon. At that time TLC indicated some
intermediate remained, so 0.5g addition Pd/ C was added and the mixture again
was heated to reflux for another 8 h. The mixture was cooled to rt, filtered and
10   concentrated on a rotovap to eliminate excess acrolein, until about 100 mL of o-
xylene solution remained. This solution was cooled by addition of ice, and was
extracted three times with 1N HCl. The combined aqueous fractions were extracted
3X with Et_2O. The aqueous phase was then cooled to 0°C and the pH was adjusted
to ~10 using concentrated NaOH. The aqueous was then extracted 5X with 100 mL
15   portions of chloroform. The combined chloroform fractions were washed with
water and then brined and dried over magnesium sulfate, filtered, and finally
concentrated to give 3.51 g of an oil in 84.4% yield of 7,8-dihydro-6H-quinolin-5-
one.

D.   The 4(5)-imidazole carboxaldehyde was condensed with the quinolinone as
20   described in Step E of Example P and was obtained both Q-1 and Q-2.

E.   The exo double bond was then reduced with palladium on carbon as
described in Step F of Example P above to yield two products which were
separated by chromatography to give Q-3 and A.

F.   The keto group was removed by the same hydrazine reduction procedure as
25   that described in Step E of Example O above to give Q4.

G.   The fully-reduced quinoline ring product Q-5 was obtained by a standard
reduction of A with lithium/ammonia. (Li, 10 equiv., in NH_3 at −78°C for 10 min,
quenched with NH_4OH, gradual warming with NH_3 evaporation).

Example R-1

Procedure for the preparation of (E)-6-(3H-imidazol-4(5)-ylmethylene)-7, 8-dihydro-6H-quinoxalin-5-one

5

Ac2O, 170°C

OHC

1) O₃, MeOH
2) Me₂S

10

piperidine, AcOH

OHC

R-1

Procedure:

A.   A mixture of 5,6,7,8-tetrahydroquinoxaline (23.75g, 1 equiv.),
15   benzaldehyde (19.81 mL, 1.1 equiv.) and acetic anhydride (33.4 mL, 2.0 equiv.)
was stirred at 150°C under argon for 15 hr, after which time TLC indicated mostly
desired product with some starting materials remaining. Starting materials were
removed by vacuum distillation using a Vigreux column at 170°C. The pot residue
was then subjected to Kugelrohr distillation from 170 – 220°C. The first fraction
20   was slightly contaminated with starting materials (4.71g). A second fraction was
pure (18.93g). After applying high vacuum to the first fraction it crystallized.
Combined fractions yielded 20.11g, 51%.

B.   The product from A, above, was dissolved in 100 mL of methanol and
warmed slightly, then cooled to –35 to –40°C and ozone was bubbled through the
25   solution. After a few minutes the starting material began to crystallize out of
solution and the solution was warmed and another 200 mL of methanol was added
and then the reaction was resumed. After about 30 minutes the solution turned pale
blue. Nitrogen was then introduced by bubbling through the solution for 30

62

minutes, then methyl sulfide (3.5 mL) was injected into the solution, whereafter the solution was stirred for another 30 min. at −35°C, then allowed to warm to ambient temperature with stirring. After about 48 hr. at 20°C the mixture was steam distilled to remove solvents to provide a residue of 8.4g of a yellow-brown oil.

5   This residue was taken up in diethyl ether and extracted 3x with 25 mL portions of 1N HCl. The combined aqueous fractions were washed with diethyl ether 3x. The aqueous solution was gradually basified to a pH of 8 with concentrated NaOH. The free amine was then extracted from the aqueous phase with chloroform (3x). The combined chloroform extracts were washed twice with brine; dried of $MgSO_4$ and

10   concentrated to a yellow oil (3.01g) After keeping under high vacuum for 1 hr., 2.97g remained. This was recrystallized from diethyl ether to give 2.35g of a bright yellow solid. Yield 67.5%.

C.   The 7,8-dihydroquinoxalin-5-one and 4(5)-imidazolecarboxaldehyde (Aldrich Chemicals) were suspended in 75 mL of anhydrous tetrahydrofuran at

15   20°C under argon followed by addition of piperidine followed by acetic acid. The mixture was stirred 16 h at 20°C. After 20 h, no traces of the quinoxalone remained as indicated by TLC. The solids were collected by filtration and washed with a small amount of tetrahydrofuran, followed by chloroform. The solid was dried under high vacuum to give 6.85g of R-1. Yield 90.3%.

20

Example R-2 and R-3

In a similar manner as R-1, 5,6,7,8-tetrahydroisoquinoline (5.42g, 1 equiv., Aldrich) was stirred with benzaldehyde (5.182 g, 1.2 equiv.) and acetic anhydride (6.309 g, 2.0 g) which was vacuum distilled and used without further purification

25   in the next step. Yield (impure): 8.28 g.

The crude product (7.96 g) from the step above was subjected to ozonolysis as described in Step B above. After work-up and chromatography there was obtained 5.18 g of a pale oil. Yield: 97.8% assuming pure starting material.

63

The resulting 7,8-dihydro-6H-isoquinolin-5-one (1.692 g, 1 equiv.) was condensed with 4(5)-imidazolecarboxaldehyde as described in Step C above to yield 2.23 g of the unsaturated compound analogous to R-1 in the scheme above in 92.8% yield. This product was treated with palladium on carbon as described in Step F of

5   Example P to reduce the exo double bond to produce 6-(3H-imidazol-4(5)-ylmethyl)-7,8-dihydro-6H-isoquinolin-5-one (R-2) in 52%.

The ketone above was reduced using hydrazine and converted to the fumarate salt as detailed in Example P, Step F. Yield for the reduction: 62%. Yield of fumarate salt after recrystallization: 30.4% of 6-(3H-imidazol-4(5)-ylmethyl)-5,6,7,8-

10   tetrahydroisoquinoline (R-3).

Example S

A method for measuring α-agonist selectivity comprises the RSAT (Receptor Selection and Amplification Technology) assay as reported in

15   Messier et al. (1995) "High throughput assays of cloned adrenergic, muscarinic, neurokinin and neurotrophin receptors in living mammalian cells", *Pharmacol. Toxicol.* 76:308-11 and adapted for use with alpha$_2$ receptors. The assay measures a receptor-mediated loss of contact inhibition that results in selective proliferation of receptor-containing cells

20   in a mixed population of confluent cells. The increase in cell number is assessed with an appropriate transfected marker gene such as b-galactosidase, the activity of which can be easily measured in a 96-well format. Receptors that activate the G protein, G_q, elicit this response. Alpha$_2$ receptors, which normally couple to G_i, activate the RSAT response

25   when coexpressed with a hybrid Gq protein that has a G_i receptor recognition domain, called $G_q/i5$[2]. See Conklin et al. (1993) "Substitution

64

of three amino acids switches receptor specificity of G_qa to that of G_ia."
Nature 363:274-6.

NIH-3T3 cells are plated at a density of 2×10^6 cells in 15 cm dishes
and maintained in Dulbecco's modified Eagle's medium supplemented

5   with 10% calf serum. One day later, cells are cotransfected by calcium
phosphate precipitation with mammalian expression plasmids encoding p-
SV-b-galactosidase (5-10 mg), receptor (1-2 mg) and G protein (1-2 mg). 40
mg salmon sperm DNA may also be included in the transfection mixture.
Fresh media is added on the following day and 1-2 days later, cells are

10   harvested and frozen in 50 assay aliquots. Cells are thawed and 100 ml
added to 100 ml aliquots of various concentrations of drugs in triplicate in
96-well dishes. Incubations continue 72-96 hr at 37°. After washing with
phosphate-buffered saline, b-galactosidase enzyme activity is determined
by adding 200 ml of the chromogenic substrate (consisting of 3.5 mM o-

15   nitrophenyl-b-D-galactopyranoside and 0.5% nonidet P-40 in phosphate
buffered saline), incubating overnight at 30° and measuring optical density
at 420 nm. The absorbence is a measure of enzyme activity, which depends
on cell number and reflects a receptor-mediated cell proliferation. The EC_{50}
and maximal effect of each drug at each alpha$_2$ receptor is determined. The

20   efficacy or intrinsic activity is calculated as a ratio of the maximal effect of
the drug to the maximal effect of a standard full agonist for each receptor
subtype. Brimonidine, also called UK14,304-18, is used as the standard
agonist for the alpha$_{2A}$ and alpha$_{2C}$ receptors. Oxymetazoline is the
standard agonist used for the alpha$_{2B}$ receptor.

25   Table 1, below, provides the intrinsic activity values at subtypes of
the α2-adrenoreceptor as determined in the RSAT assay for the compounds

65

of above Examples B through R and certain adrenergic compounds not

having selective agonist activity at the α2B or α2B /α2C subtype(s). At the

α2A subtype, the compounds of the Examples are inactive or exhibit low

efficacy (≤0.4). They have greater efficacy at the α2B and the α2C-

5   subtypes than the α2A-subtype. Therefore, unlike ophthalmic α2-

adrenoreceptor compounds such as clonidine and brimonidine, the

compounds of Examples B through R can selectively activate α2-

adrenoreceptor subtypes other than the α2A-subtype.

Table 1: Intrinsic Activity Relative to Brimonidine/Oxymetazoline

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
	oxymetazoline	0.63	1.0	0.58
	clonidine	0.78	0.75	0.55
	brimonidine	1.0	0.93	1.0
	4(5)-(3-methyl-thiophen-2-ylmethyl)-1H-imidazole	0.43	1.4	0.5
D-3	bicyclo[2.2.1]hept-2-yl oxazolidin-2-ylidene amine	0	0.4	0

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
D-1	oxazolidin-2-ylidene-(3-phenyl bicyclo[2.2.1]hept-2-yl) amine	0	0.47	0
F	6-(imidazolidin-2-ylidene amino)-5-methyl-4H-benzo[1,4]oxazin-3-one	0.3	0.9	0.2
G	imidazolidin-2-ylidene-(5-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-8-yl) amine, hydrogen chloride salt	0.1	0.87	0.33
J-1	4(5)-cyclohexylmethyl-1H-	0.1	0.83	0

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
	imidazole			
E-1	imidazolidin-2-ylidene-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl) amine	0.33	0.83	0.35
M	4(5)-(2,3-dihydro benzo[1,4]dioxin-6-ylmethyl)-4-methyl-1H-imidazole	0.2	0.97	0.27
C-2	4(5)-thiophen-2-ylmethyl-1H-imidazole	0.23	1.3	0.5
C-1	4(5)-thiophen-3-ylmethyl-1H-imidazole	0	0.83	0

68

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
C-9	4(5)-benzo[b]thiophen-2-ylmethyl-1H-imidazole	0.06	0.88	0.43
C-3	4(5)-(5-methylthiophen-2-ylmethyl)-1H-imidazole	0.1	0.88	0.43
C-8	4(5)-benzyl-1H-imidazole	0.3	0.9	0.4
H	4(5)-phenylsulfanyl-1H-imidazole	0.2	0.93	0.15
C-5	4(5)-furan-2-ylmethyl-1H-imidazole	0	1.1	0.4

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-3b	4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole	0	0.7	0
J-2	(S)-4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole	0	0.8	0
J-3	(R)-4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole	0.1	1	0.15
L	4(5)-(1-furan-2-ylethyl)-1H-imidazole	0.23	0.9	0.57
C-6	4(5)-furan-3-ylmethyl-1H-imidazole	0.2	0.67	0.1

70

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
C-4	4(5)-(5-chlorothiophen-2-ylmethyl)-1H-imidazole	0.05	0.82	0.5
D-2	oxazolidin-2-ylidene-(3-o-tolyl bicyclo[2.2.1]hept-2-yl) amine	0.25	0.75	0
C-10	4(5)-benzofuran-2-ylmethyl-1H-imidazole	0.05	0.48	0.1
C-7	4(5)-(5-methylfuran-2-ylmethyl)-1H-imidazole	0.08	0.73	0.2

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-3a	2-(3H-imidazol-4(5)-ylmethyl)-3,4-dihydro-2H-naphthalen-1-one	0.1	0.8	0.07
I	4(5)-(1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-4,5-dihydro-1H-imidazole, methane sulfonic acid salt	0	0.5	0.2
B-2a	3-(3H-imidazol-4(5)-ylmethylene)chroman-4-one	0	0.63	0.15
B-2b	3-(3H-imidazol-4(5)-ylmethyl)chroman-4-one	0	0.77	0

72

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-2d	4(5)-chroman-3-ylmethyl-1H-imidazole	0	0.6	0
B-2c	3-(3H-imidazol-4(5)-ylmethyl)chroman-4-ol	0	0.65	0
B-9a	4(5)-(4,5,6,7-tetrahydrobenzo[b]thiophen-5-ylmethyl)-1H-imidazole	0.08	0.46	0
B-4a	4(5)-(4-methyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole	0	0.75	0.1

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-4b	2-(3H-imidazol-4(5)-ylmethyl)-4-methyl-3,4-dihydro-2H-naphthalen-1-one	0.3	0.7	0.6
B-11b	6-(1H-imidazol-4(5)-ylmethylene)-6,7,8,9-tetrahydrobenzocyclohepten-5-one	0	0.3	0
B-6	4(5)-thiochrom-3-ylmethyl-1H-imidazole, hydrogen chloride salt	0	0.35	0
B-5b	3-(3H-imidazol-4(5)-ylmethyl)thiochroman-4-one	0	0.5	0.2

74

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-5a	3-(3H-imidazol-4(5)-ylmethylene)thiochroman-4-one	0	0.5	0.37
B-7a	2-(3H-imidazol-4(5)-ylmethylene)indan-1-one	0	0.3	0
B-11a	4(5)-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl)-1H-imidazole	0.4	0.9	0
B-7b	2-(3H-imidazol-4(5)-ylmethyl)indan-1-one	0	0.3	0

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
B-1	HCl 4(5)-(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole, hydrogen chloride salt	0.15	0.45	0.3
B-1a	2-(3H-imidazol-4(5)-ylmethyl)-7-methoxy-3,4-dihydro-2H-naphthalen-1-one	0.15	0.6	0
B-9b	HCl 5-(3H-imidazol-4(5)-ylmethyl)-6,7-dihydro-5H-benzo[b]thiophen-4-one, hydrogen chloride salt	0	0.68	0.15
B-7c	4(5)-indan-2-ylmethyl-1H-imidazole	0	0.9	0

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymctazoline Alpha 2B	Brimonidine Alpha 2C
B-10	4(5)-(4,4-dimethyl-1,2,3.4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole	0	0.3	0
B-8b	4(5)-(7-methyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)-1H-imidazole, hydrogen chloride salt	0	0.6	0.2
B-8a	2-(3H-imidazol-4(5)-ylmethyl)-7-methyl-3.4-dihydro-2H-naphthalen-1-one	0	0.4	0
K-1	4(5)-(4,5,6,7-tetrahydrobenzo[b]thiophen-2-ylmethyl)-1H-imidazole	0	0.53	0

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
C-12	4(5)-(4-bromothiophen-2-ylmethyl)-1H-imidazole	0.2	1.3	0.3
C-13	4(5)-(4-phenylthiophen-2-ylmethyl)-1H-imidazole	0	0.5	0
K-3	4(5)-(5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-ylmethyl)-1H-imidazole	0	0.37	0
K-2	4(5)-(5-tert-butylfuran-2-ylmethyl)-1H-imidazole	0	0.7	0
C-11	4(5)-(5-ethylfuran-2-ylmethyl)-1H-imidazole	0.2	0.5	0

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
C-14	4(5)-(4-methylthiophen-2-ylmethyl)-1H-imidazole, hydrochloride salt	0.27	0.7	0.3
N-1	2-(3H-imidazol-4(5)-ylmethyl)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one, hydrochloride salt	0.24	0.75	0.26
Q-3	6-(3H-imidazol-4(5)-ylmethyl)-7,8-dihydro-6H-quinolin-5-one	0.1	0.9	0.23
Q-2		0.1	0.87	0.13

| Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
	(E)-6-(3H-imidazol-4(5)-ylmethylene)-7,8-dihydro-6H-quinolin-5-one			
Q-1	(Z)-6-(3H-imidazol-4(5)-ylmethylene)-7,8-dihydro-6H-quinolin-5-one	0	0.75	0.2
N-2	4(5)-(2,3,4,4a,5,6,7,8-octahydronaphthalen-2-ylmethyl)-1H-imidazole	0	0.5	0.05
Q-4	6-(3H-imidazol-4(5)-ylmethyl)-5,6,7,8-tetrahydro-quinoline, dihydrochloride	0.1	0.8	0.1

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
O	4(5)-octahydro pentalen-2-ylmethyl-1H-imidazole, hydrochloride	0	0.67	0.1
B-9c	5-(octahydro benzo[b]thiophen-5-ylmethyl)-1H-imidazole, hydrochloride	0	0.3	0
R-3	6-(3H-imidazol-4(5)-ylmethyl)-5,6,7,8-tetrahydro-isoquinoline, fumarate	0	0.6	0.4
R-2	6-(3H-imidazol-4(5)-ylmethyl)- 7,8-dihydro-6H-isoquinolin-5-one, dihydrochloride	0	0.6	0.4

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
R-1	(E)-6-(3H-imidazol-4(5)-ylmethylene)- 7,8-dihydro-6H-quinoxalin-5-one	0.3	0.8	0.4
P-1	7-(3H-imidazol-4(5)-ylmethyl)- 6,7-dihydro-5H-isoquinolin-8-one, fumarate	0	0.4	0
P-2	7-(3H-imidazol-4(5)-ylmethyl)- 5,6,7,8-tetrahydro-isoquinoline, fumarate	0	0.4	0
N-3		0	0.75	0

Example	Structure/Compound	Brimonidine Alpha 2A	Oxymetazoline Alpha 2B	Brimonidine Alpha 2C
	4(5)-(1,2,3,4,5,6,7,8-octahydronaphthalen-2-ylmethyl)-1H-imidazole, fumarate			
Q-5	H N ... HN N ... O 6-(3H-imidazol-4(5)-yl-methyl)-octahydroquinolin-5-one	0	1.0	0

Example T

IOP-Lowering and Sedative Side Effects

Measurements of IOP were made in fully conscious female cynomolgus monkeys weighing 3-4 kg with sustained elevated IOP that was produced in the right eye by argon laser photocoagulation of the trabecular meshwork. Animals were usable for experiments ~ 2 months following surgery. During the experiments, monkeys sat in specially designed chairs (Primate Products, San Francisco), and were fed orange juice and fruit as needed. A 30R model Digilab pneumatonometer (Alcon, Texas) was used to measure IOP.

Twenty five μl of an anesthetic (proparacaine) was topically applied to each monkey before IOP measurements to minimize ocular discomfort due to tonometry. Two baseline measurements were made prior to instillation of the drugs, followed by periodic measurements up to 6 hours

83

post-instillation. The test compounds were administered unilaterally as a single 50 µl eye drop; the contralateral eyes received an equal volume of saline.

Many of the α2B or α2B/2C selective compounds of the examples

5   were tested in the monkeys. Surprisingly, as Table 2 shows, these structurally diverse compounds all lowered IOP in the treated eye.

At the same time, sedation was measured and assessed according to the following score: 0 = alert, typical vocalization, movement, etc.; 1 = calm, less movement; 2= slightly sedated, some vocalization, responsive to

10   stimulation; 3 = sedated, no vocalization, some response to stimulation; 4 = asleep.

The compounds of the present invention also did not cause sedation. This contrasts with the action of clonidine and brimonidine, which caused sedation.

15

Table 2. The effects of α_2-adrenoceptor agonists on IOP and sedation in conscious cynomolgus monkeys following ocular administration in eyes made unilaterally hypertensive by argon laser photocoagulation. Measurements were made periodically up to 6 hours. Sedation was assessed subjectively during the IOP

20   experiments using the following scoring: 0 = alert, typical vocalization, movement, etc.; 1 = calm, less movement; 2 = slightly sedated, some vocalization, responsive to stimulation; 3 = sedated, no vocalization, some response to stimulation; 4 = asleep. Number of animals per group = (6-9).

25

Table 2		Maximum % Decrease From Pretreatment Levels	
Compounds	Dose (%)	Hypertensive Eye	Sedation (0-4)
Saline	-	7 ± 2	0-1
Clonidine	0.1	25 ± 4	1
	0.3	41 ± 5	2
Brimonidine	0.1	25 ± 3	1
	0.3	40 ± 4	2
J-1	1	26 ± 5	0
	3	33 ± 3	0
E-1	0.3	25 ± 4	0
	1	27 ± 3	0
C-1	1	25 ± 4	0
	3	29 ± 4	0
D-1	1	25.6 ± 3.9	0
M	1	22.5 ± 5.4	0
C-2	1	29.6 ± 5.5	0

85

C-9	0.3	13.7 ± 4.5	0
	1	25.1 ± 4.9	0
C-3	0.3	20.6 ± 4.8	0
	1	25.0 ± 6.4	0
C-8	1	31.2 ± 3.3	0
B-3b	0.1	25.9 ± 3.5	0
	0.3	31.2 ± 4.3	0
C-4	0.3	17.7 ± 4.0	0
	1	29.3 ± 4.9	0
C-7	1	32.3 ± 5.7	0
J-2	0.03	12.4 ± 3.7	0
	0.3	27.3 ± 3.1	0
J-3	0.03	16.4 ± 4.7	0
	0.3	26.5 ± 3.8	0
B-2d	0.1	22.0 ± 4.6	0
	0.3	17.0 ± 4.2	0
	1	18.1 ± 5.2	0

86

B-9a	0.03	17.6 ± 1.7	0
	0.1	26.7 ± 6.1	0
	0.3	24.8 ± 3.3	0
	1	26.8 ± 5.4	0
B-6	0.3	13.8 ± 2.4	0
	1	22.1 ± 6.3	0
B-9b	0.1	18.7 ± 5.5	0
	0.3	26.9 ± 6.1	0

Example U

Measurement of Cardiovascular Side Effects

5   Cardiovascular measurements were made in a different group of
monkeys using a BP 100S automated sphygmomanometer (Nippon Colin,.
Japan). Intravenous (IV) administration of certain of the compounds of the
present invention at doses ten to thirty times higher than the doses for
clonidine and brimonidine did not reduce heart rate or lower blood
10   pressure. Interestingly, the compound 4(5)-3-methylthiophen-2-ylmethyl)-
1H-imidazole, which has intrinsic activity of 0.43 at the α2A-subtype,
exhibited a weak effect on heart rate. Clonidine and brimonidine had even
greater effects on heart rate. See Table 3 below.

      Table 3. The effects of α_2-adrenoceptor agonists on cardiovascular
15   variables in conscious cynomolgus monkeys following i.v. administration.
Measurements were made periodically up to 6 hours. Number of animals per
group = (6-10).

Table 3		Maximum % Decrease From Pretreatment Levels	
Compounds	Dose (μg/kg)	Mean Arterial Blood Pressure	Heart Rate
Saline	-	7 ± 4	8 ± 3
Clonidine	17	29 ± 7	32 ± 4
	50	35 ± 5	50 ± 5
Brimonidine	17	36 ± 3	52 ± 3
	50	37 ± 5	54 ± 3
J-1	17	7 ± 5.3	13 ± 4
	50	4 ± 2	6 ± 2
	167	7 ± 5	3 ± 3
	500	13 ± 3	7 ± 4
E-1	17	7 ± 4	11 ± 4
	50	7 ± 2	14 ± 5
	167	9 ± 4	11 ± 5
C-1	50	12.8 ± 12	12 ± 4
	500	+5 ± 8*	+11 ± 9*
M	500	0.8 ± 2.3	5.5 ± 1.9
C-2	500	6.6 ± 1.7	6.5 ± 2.9
C-9	3.0	5.0 ± 2.3	9.4 ± 3.0
	17	1.0 ± 4.1	+9.4 ± 1.8*
	50	0.1 ± 3.8	16 ± 3.2
	500	6.0 ± 2.2	5.9 ± 3.3
C-3	500	2.3 ±2.7	10.6 ± 3.4
C-8	500	5.5 ± 2.7	16.6 ± 1.9
C-5	500	3.9 ± 2.8	7.1 ± 3.9
B-3b	50	2.4 ± 4.3	10.0 ± 2.8
C-4	500	5.3 ± 2.9	10.9 ± 3.6

88

C-7	500	3.0 ± 3.9	6.1 ± 3.7
J-2	500	+0.6 ± 3.1*	6.4 ± 3.3
J-3	500	+1.0 ± 2.1*	+10.6 ± 6.0*
B-2b	500	5.7 ± 1.4	6.4 ± 3.6
B-2d	500	+8.9 ± 3.4*	+15.5 ± 3.4*
B-9a	500	+10.8 ± 3.2*	+23.8 ± 4.4*
B-9b	500	2.8 ± 1.8	+20.2 ± 3.4*
4(5)-(3-methylthiophen-2-ylmethyl)-1H-imidazole	50	9 ± 3	23 ± 4
	167	8 ± 6	32 ± 8

* showed increase from base levels

EXAMPLE V

The studies in the above Examples T and U demonstrate that a

5   therapeutic effect of alpha2 agonists can be separated from sedative and
cardiovascular side effects. This separation is accomplished with compounds
that share the property of being preferentially active at the alpha2B and
alpha2B/alpha2C subtypes relative to the alpha2A subtype.

The prior art alpha2 adrenergic agonists, which activate all three alpha2

10   receptors, cause sedation, hypotension and bradycardia, preventing or
severely limiting their use for treating diseases and disorders that are known
to be ameliorated by them. Such diseases and disorders include muscle
spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal
syndromes, pain including neuropathic pain, neurodegenerative diseases

15   including optic neuropathy, spinal ischemia and stroke, memory and
cognition deficits, attention deficit disorder, psychoses including manic
disorders, anxiety, depression, hypertension, congestive heart failure, cardiac

89

ischemia and nasal congestion. See, for example, Hieble et al., "Therapeutic applications of agents interacting with alpha-adrenoceptors, in Alpha-adrenoceptors: molecular biology, biochemistry and pharmacology". *Prog. Basic Clin. Pharmacol.* (Basel, Karger) 8, pp. 180-220(1991). For example,

5   clonidine has been shown to be clinically effective in providing pain relief for postoperative, cancer-associated and neurogenic pain. But, as stated in Maze and Tranquilli, Maze MB and Tranquilli, W. "Alpha-2 adrenoceptor agonists: defining the role in clinical anesthesia". *Anesthesiology* 74, 581-605 (1991), the "full clinical promise" of this and other alpha2 agonists requires the

10   development of compounds that do not cause sedation, hypotension and bradycardia.

The above-listed diseases and disorders are treatable by activation of α2B or α2B/2C receptor subtype(s). Therefore, the alpha2 compounds described above that have been shown above not to elicit sedation and

15   cardiovascular effects, are useful and advantageous in the treatment of these conditions.

Amelioration of neuronal degeneration in glaucomatous neuropathy is another example of the novel utility of the compounds of the invention. Recent studies have demonstrated that clonidine and other alpha2 agonists are

20   neuroprotective of retinal cells in several rat models of neuronal degeneration. These models include light-induced photoreceptor degeneration in albino rat, as described in Wen et al, "Alpha2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage." *J. Neurosci.* 16, 5986-5992 and calibrated rat optic nerve injury

25   resulting in secondary loss of retinal ganglion cells, as described in Yoles et al, "Injury-induced secondary degeneration of rat optic nerve can be attenuated

90

by alpha2-adrenoceptor agonists AGN 191103 and brimonidine". *Invest.*
Ophthalmol. Vis. Sci. 37, 540,S114. However, unlike the compounds of the
present invention, the doses used in these studies -- 0.1 to >1 mg/kg by
intraperitoneal or intramuscular injection-- also cause sedation and

5   cardiovascular effects. Induction of the expression of basic fibroblast growth
factor (bFGF) is considered a sensitive indicator of alpha2 receptor activation
in the retina (Wen et al above) and measurement of bFGF induction following
topical administration of alpha2 agonists to rat eyes indicates that
approximately a 1% dose is necessary to induce a 2-3 fold increase in bFGF

10   levels that correspond with alpha2 agonist mediated neuroprotection (See Wen
et al, above, and Lai et al, "Neuroprotective effect of ocular hypotensive agent
brimonidine", in *Proceedings of XIth Congress of the European Society of*
Ophthalmology (Bologna, Monduzzi Editore), 439-444.) These topical doses of
current alpha2 agonists such as clonidine are known to result in systemic side

15   effects such as sedation and hypotension that would prevent their use as
ocular neuroprotective agents. Additionally commonly assigned and co-
pending application, 08/496,292 filed on 28 June, 1995, discloses and claims
the use of certain non-selective α2-adrenergic agents in treating neural injury,
the contents of which are hereby incorporated by reference in their entirety.

20   The compounds of the present invention do not cause sedation and
cardiovascular effects following topical administration of doses of at least 3%
in monkeys. Thus, neuroprotective concentrations of these compounds can be
reached in humans without causing side effects. In fact, as reported below, the
compound of Example B-9(b) has been shown to be neuroprotective in the

25   calibrated rat optic nerve injury model of Yoles et al, above. See Table 4,
below.

91

Table 4: Retinal Ganglion Cell Numbers at 2 Weeks Post-Injury
(cells/microscopic field)

Control (vehicle i.p.)	Example B-9(b) (0.5 mg/kg i.p.)
33 ± 8	73 ± 12
n = 8	n = 5

5   This level of neuroprotection is comparable to the effect seen in previous

studies with the standard alpha 2-adrenoceptor agonist, brimonidine, and the

neuroprotective agent, MK801.

Example W

Alleviation of pain including neuropathic pain is another example of a

10   disorder in which the compounds of the invention are useful and

advantageous since pain is alleviated without undesirable side effects.

Clonidine, an agonist that activates all three alpha2 receptors, has been

used clinically for treating chronic pain, but its utility for this indication is

limited because it causes sedation and cardiovascular side effects.

15   Compounds of the present invention were compared to clonidine and

brimonidine in a rodent model of neuropathic pain that is known to be

predictive of clinical activity. (See, for example, Kim, S. and Chung, J. "An

experimental model for peripheral neuropathy produced by segmental

spinal nerve ligation in the rat." *Pain* 50 pp. 355-363 (1992).) Following

20   ligation of two spinal nerves, the animals develop a sensitivity to normally

non-painful stimuli such as touch. The ability of alpha2 compounds to

reverse this sensitivity, called allodynia, was tested 30 minutes after dosing

by either intrathecal or intraperitoneal administration. The sedative activity

of each compound was also measured using an activity chamber.

The compounds of the invention, exemplified by N-1, are able to alleviate the allodynia without causing sedation, even at very high doses. This is in contrast to clonidine and brimonidine, which cause sedation at doses only

5   slightly higher than their anti-allodynic doses. See tables 5 and 6, below.

Table 5. The anti-allodynic and sedative effects of alpha2-adrenoceptor agonists in rats 30 minutes following intrathecal administration (N=6).

Compound	Dose (μg)	Reversal of Tactile Allodynia (%)	Sedation (%)
Clonidine	0.1	20*	ND
	1	96*	15
	10	ND	60*
N-1	3	13	ND
	30	64*	0
	300	ND	0

10   * p<0.05 compared to saline control

• ND signifies no data

Table 6. The anti-allodynic and sedative effects of alpha2-adrenoceptor agonists in rats 30 minutes following intraperitoneal administration (N=6).

15

Compound	Dose (mg/kg)	Reversal of Tactile Allodynia (%)	Sedation (%)
Brimondine	3	0	ND
	30	37*	24
	300	ND	67*

(Table 6 con't.) Compound	Dose (mg/kg)	Reversal of Tactile Allodynia (%)	Sedation (%)
N-1	3	3	ND
	30	41*	ND
	10,000	ND	0

*, p<0.05 compared to saline control

- ND signifies no data

5   The results of these Examples demonstrate that the common side effects of α2-adrenoceptor drugs are mediated by the α2A-subtype and that their ocular antihypertensive and other therapeutic actions can be mediated by a subtype other than the α2A-subtype. Thus, α2-adrenoceptor compounds of unrelated structural classes, that have in common low

10   functional activity at the α2A-subtype, lower IOP and elicit other therapeutic actions without dose-limiting side effects.

While particular embodiments of the invention have been described, it will be understood, of course, that the invention is not limited thereto since many obvious modifications can be made, and it is intended to

15   include within this invention any such modification as will fall within the scope of the appended claims.

Having now described the invention, we claim:

WHAT IS CLAIMED IS:

1.   A compound having selective agonist activity at the α2B or α2B/α2C

adrenergic receptor subtype(s) as compared to the 2A adrenergic receptor

subtype represented by the formula

I

wherein the dotted lines represent optional double bonds; R is H or lower

alkyl; X is S or C(H)R', wherein R' is H or lower alkyl or R' is absent when

X is S or when the bond between X and the ring represented by

is a double bond; Y is O, N, S, $(CR^1_x)_y$, wherein y is an integer of from 1 to 3,

-CH=CH- or -Y'CH$_2$-, wherein Y' is O, N or S; x is an integer of 1 or 2,

wherein x is 1 when R^2, R^3 or R^4 is bound to an unsaturated carbon atom

and x is 2 when R^2, R^3 or R^4 is bonded to a saturated carbon atom; R^2 is H,

lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a

saturated carbon atom, R_2 may be oxo; R_3 and R_4 are, each, H, lower alkyl,

hydroxy, lower alkoxy, or phenyl or, together, are $-(C(R^2)x)z-$;

95

$-Y'(C(R^2)x)z'-; - Y' (C(R^2)x)y \ Y'-; -(C(R^2)x)- Y'-(C(R^2)x)-; -(C(R^2)x)- Y'-$
$(C(R^2)x)-(C(R^2)x)- \ and - Y'-(C(R^2)x)- Y'-(C(R^2)x)-$ wherein z is an integer of
from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above,
and further either end of each of these divalent moieties may attach at

5   either R^3 or R^4 to form the condensed ring structure

and the ring thus formed may be totally unsaturated, partially unsaturated,
or totally saturated provided that a ring carbon has no more than 4

10   valences, nitrogen no more than three and O and S have no more than two,
and including pharmaceutically acceptable salts thereof.

       2.   A compound according to claim 1 wherein said compound is
   represented by the formula

15

20

       3.   A compound according to claim 2 wherein X is C(H)R^1.

       4.   A compound of claim 3 wherein R^1 is H.

5.   A compound of claim 4 wherein R_2 is H and

represents a furanyl radical.

6.   A compound of claim 5 wherein R^3 and R^4 together are $(CH)_4$.

7.   A compound of claim 5 wherein R^3 is H and R^4 is t-butyl.

8.   A compound of claim 5 wherein R^3 and R^4 are H.

9.   A compound of claim 5 wherein R^3 is H and R^4 is methyl or ethyl.

10.   A compound of claim 4 wherein R^2 is H and

represents a thienyl radical.

11.   A compound of claim 10 wherein R^3 and R^4, together, represent $(CH_2)_4$.

12.   A compound of claim 10 wherein R^3 is phenyl and R^4 is H.

13. A compound of claim 10 wherein R^3 and R^4, together, represent $(CH_2)_3S$.

14. A compound of claim 10 wherein R^3 and R^4 are H.

5

15. A compound of claim 10 wherein R^3 and R^4, together, represent $(CH)_4$.

16. A compound of claim 10 wherein R^3 is H and R^4 is methyl.

10

17. A compound of claim 10 wherein R^3 is bromo and R^4 is H.

18. A compound of claim 4 wherein

15 represents a cyclohexyl radical.

19. A compound of claim 18 wherein R^2 is H, and R^3 and R^4, together, represent $(CH)_4$.

20 20. A compound of claim 18 wherein R^2 is H, and R^3 and R^4, together, represent $(CH)_2S$.

21. A compound of claim 18 wherein R^2 is H, and R^3 and R^4, together, represent $(CH_2)_4$.

25

22.   A compound of claim 18 wherein R^2 is dimethyl, and R^3 and R^4, together, represent $(CH)_4$.

23.   A compound of claim 18 wherein Y is $-CH_2CH(CH_3)-$, R^2 is hydrogen or oxo, and R^3 and R^4, together, represent $(CH)_4$.

24.   A compound of claim 18 wherein R^2 is oxo, and R^3 and R^4, together, represent $S(CH)_2$.

25.   A compound of claim 18 wherein Y is $-CH_2C(CH_3)_2-$, R^2 is hydrogen or oxo, and R^3 and R^4, together, represent $(CH)_4$.

26.   A compound of claim 18 wherein R^2 is oxo, and R^3 and R^4, together, are $(CH)_4$.

27.   A compound of claim 18 wherein R^2 is oxo, and R^3 and R^4, together, represent $(CH)_2 C(OCH_3)CH$.

28.   A compound of claim 4 wherein

represents a cyclopentyl radical.

29.   A compound of claim 28 wherein R^2 is H, and R^3 and R^4, together, represent $(CH)_4$.

30.   A compound of claim 28 wherein R^2 is hydrogen, and R^3 and R^4,
together, represent $(CH_2)_3$.

31.   A compound of claim 4 wherein

5

represents a benzyl radical.

32.   A compound of claim 31 wherein R^2, R^3 and R^4 are H.

10   33.   A compound of claim 1 wherein said compound has the formula

wherein Y is S or O.

34.   A compound of claim 33 wherein X is $C(H)R^1$ and R, R^1, R^2, R^3 and
15   R^4 are H.

35.   A compound of claim 34 wherein Y is O.

36.   A compound of claim 35 wherein Y is S.

20

100

37.   A compound of claim 1 wherein said compound has the formula

38.   A compound of claim 37 wherein R^3 and R^4, together, represent

5    $(CH)_4$.

39.   A compound of claim 38 wherein Y^1 is O.

40.   A compound of claim 39 wherein R^2 is oxo.

10

41.   A compound of claim 40 wherein X is CH.

42.   A compound of claim 40 wherein X is CH_2.

15   43.   A compound of claim 39 wherein one of R^2 is hydroxy and the other
       is H.

44.   A compound of claim 39 wherein R^2 is H.

20   45.   A compound of claim 38 wherein Y^1 is S.

46.   A compound of claim 45 wherein X is CH_2.

47.   A compound of claim 46 wherein R^2 is oxo.

48.   A compound of claim 46 wherein R^2 is H.

49.   A compound of claim 45 wherein X is CH and R^2 is oxo.

50.   A compound of claim 3 wherein Y is $(CH_2)_3$.

51.   A compound of claim 50 wherein X is CH and R^2 is oxo.

52.   A compound of claim 50 wherein X is CH_2 and R^2 is H.

53.   A compound of claim 2 wherein X is S and

is phenyl.

54.   A compound of claim 3 wherein R^1 is methyl and

is furanyl.

55. A compound of claim 4 wherein Y is $CH_2(CR^1_2)_2$ wherein R^1 is hydrogen or methyl.

56. A compound of claim 55 wherein R^2 is H.

57. A compound of claim 55 wherein R^2 is oxo.

58. A compound of claim 3 wherein R is CH_3,

represents a phenyl radical and R3 and R4, together represent $O(CR_2)_2O$.

59. A compound of claim 2 wherein X is CH,

represents a cyclopentyl radical and R_2 is oxo.

60.   A compound represented by the formula

61.   A compound according to claim 1 represented by the formula

wherein Y is $(R^1_x)_2$, $R^3 + R^4$ is $(C(R^2)_x)_4$ and X attaches at one of the two positions of the ring indicated by the wavy line with the remaining position being occupied by hydrogen, provided that two double bonds may not occupy the same ring atom.

62.   A compound according to claim 61 wherein said compound is represented by the formula


wherein $(R^2)_x$ is hydrogen or oxo.

63.   A compound of claim 61 wherein the structure is

64.   A compound of claim 62 wherein the structure is

5   65.   A compound of claim 2 wherein R is hydrogen, R3 + R4 are −

$(C(R^2)_x)$-N-$(C(R^2)_x)$-$(C(R^2)_x)$-, and X is CHR^1 as represented by the formula

10

the CHR^1 group attaches at one of the two positions of the ring indicated by the wavy line with the remaining position being occupied by hydrogen, and provided that two double bonds may not occupy the same ring atom.

15

66.   A compound of claim 65 wherein said compound has the formula

20

and $(R^2)_x$ is hydrogen or oxo.

67.   A compound of claim 65 wherein said compound has the formula

5   and $(R^2)_x$ is hydrogen or oxo.

68.   A compound of claim 1 wherein R3 + R4 are chosen from the group consisting of $-Y^1-(C(R^2)x)-$ $(C(R^2)x)-$ Y^1- and $-Y^1(C(R^2)x)-(C(R^2)x)-(C(R^2)x)-$, and Y^1 is N or O or S as represented by the formula

10

wherein X and X′ are selected from the group consisting of N, O, and C and

15   at least one of X and X′ are N.

69.   A compound according to claim 68 wherein said compound is represented by the formula

20

wherein $(R^2)_x$ is hydrogen or oxo.

25 70.   A compounds according to claim 68 wherein said compound is represented by the formula

106

5   wherein $(R_2)_x$ is hydrogen or oxo.

71.   A compound having selective agonist activity at the α2B or α2B/2C
adrenergic receptor or α2B and α2C adrenergic receptor subtype(s) as
compared to the α2A adrenergic receptor subtype represented by the

10   formula

and pharmaceutically acceptable salts thereof.

72.   A process for administering to a host mammal, including a human
being, a pharmaceutical composition containing an effective dose of an
active compound to treat or prevent glaucoma without sedating or

15   cardiovascular side effects, wherein said compound has adrenergic activity
and is a selective agonist of the α2B adrenoceptor subtype or α2B/α2C
adrenoceptor subtype(s) in preference over the α2A adrenoceptor subtype.

73.   A process of claim 72 wherein the active compound has an efficacy

20   relative to a standard full agonist that is at least approximately 0.3 greater
at the α2B or α2C adrenoreceptor subtypes than at the α2A adrenoreceptor
subtype and its efficacy at the α2A adrenoreceptor subtype is ≤ 0.4.

74.   A process of claim 72 wherein the active compound is at least ten
times more potent at the α2B or α2C adrenoceptor subtype than at the α2A
adrenoceptor receptor.

5

75.   A process of claim 74 wherein approximately 0.001% to 5% by
weight of the active compound is administered topically to the host
mammal in daily or twice daily doses.

10   76.   A process of claim 75 wherein approximately 0.01% to 3% by weight
of the active compound is administered topically to the host mammal in
daily or twice daily doses.

77.   A process of claim 72 wherein said compound has no activity at the
15   α2A adrenoreceptor subtype.

78.   A process of claim 72 wherein said compound has no activity at the
α2A and α2C adrenoreceptor subtypes.

20   79.   A process for administering to a host mammal, including a human
being, a pharmaceutical composition containing an effective dose of an
active compound to treat elevated intraocular pressure without sedating or
cardiovascular side effects, wherein the compound has adrenergic activity
and is a selective agonist of the α2B or α2B/α2C adrenoceptor subtype(s) in
25   preference over the α2A adrenoceptor receptor subtype.

80.   A process of claim 79 wherein the active compound has an efficacy relative to a standard full agonist that is at least approximately 0.3 greater at the α2B or 2C adrenoceptor subtypes than at the α2A adrenoceptor subtype, and its efficacy at the α2A adrenoceptor subtype is $\leq$ 0.4.

5

81.   A process of claim 80 wherein approximately 0.001% to 5% by weight of the active compound is administered topically to the host mammal in daily or twice daily doses.

10   82.   A process of claim 81 wherein approximately 0.01% to 3.0% by weight of the active compound is administered topically to the host mammal in daily or twice daily doses.

83.   A process of claim 79 wherein said compound has no activity at the
15   α2A adrenoreceptor subtypes.

84.   A process of claim 79 wherein said compound has no activity at the α2A and α2C adrenoreceptor subtypes.

20   85.   A method of treating a mammal to lower intraocular pressure without having cardiovascular and sedative side effects by selectively agonizing the α2B adrenoceptor subtype or α2B/α2C adrenoceptor subtype(s) in preference to the α2A adrenoceptor subtype.

25   86.   A method of selectively agonizing the α2B adrenoceptor subtype or α2B/α2C adrenoceptor subtypes without agonizing the α2A adrenoceptor

subtype comprising administering a therapeutically effective amount of a

selective α2B or α2B/α2C receptor subtype agonist(s) respectively.

87.   An alpha adrenergic agonist that selectively activates the α2B or

α2B/α2C receptor subtype(s) in preference to the α2A receptor subtype.

88.   A process according to claims 72, 79, 85 or 91 wherein the active

compound is selected from the group consisting of compounds having the

formula

I

wherein the dotted lines represent optional double bonds; R is H or lower

alkyl; X is S or $C(H)R^1$, wherein R^1 is H or lower alkyl or R^1 is absent when

X is S or when the bond between X and the ring represented by

is a double bond; Y is O, N, S, $(CR^1_x)_y$, wherein y is an integer of from 1 to 3,

-CH=CH- or $-Y^1CH_2-$, wherein Y^1 is O, N or S; x is an integer of 1 or 2,

wherein x is 1 when R^2, R^3 or R^4 is bound to an unsaturated carbon atom

and x is 2 when R^2, R^3 or R^4 is bonded to a saturated carbon atom; R^2 is H,

lower alkyl, halogen, hydroxy or lower alkoxy, or, when attached to a

saturated carbon atom, R_2 may be oxo; R_3 and R_4 are, each, H, lower alkyl, hydroxy, lower alkoxy, or phenyl or, together, are $-(C(R^2)x)z-$; $-Y^1(C(R^2)x)z'-$; $- Y^1 (C(R^2)x)y\ Y^1-$; $-(C(R^2)x)- Y^1-(C(R^2)x)-$; $- (C(R^2)x)- Y^1-(C(R^2)x)-(C(R^2)x)-$ and $- Y^1-(C(R^2)x)- Y^1-(C(R^2)x)-$ wherein z is an integer of

5   from 3 to 5, z′ is an integer of from 2 to 4 and x and y are as defined above, and further either end of each of these divalent moieties may attach at either R^3 or R^4 to form the condensed ring structure

and the ring thus formed may be totally unsaturated, partially unsaturated,

10   or totally saturated provided that a ring carbon has no more than 4 valences, nitrogen no more than three and O and S have no more than two; or

15   wherein W is a bicyclic radical selected from the group consisting of

wherein R^5, R^6, R^7 and R^8 are selected from the group consisting of H and lower alkyl provided that at least one of R^5 and R^6 or R^6 and R^7 are $OC(R^9)C(R^9)N(R)$ to form a condensed ring with

5

wherein R^9 is H, lower alkyl or oxo

and

wherein R^{10} is H, lower alkyl, phenyl or lower alkyl substituted phenyl,

10   and Z is O or NH.

89.   A process for administering to a host mammal, including a human being, a pharmaceutical composition containing an effective dose of an active compound, having adrenergic activity, to treat or prevent glaucoma

15   wherein the active compound has the biological property that the compound is a selective agonist of α2B or α2B/α2C receptor subtype(s) in

preference over the α2A receptor subtype, said selectivity being measured

in an assay using cells that naturally express the individual α2 subtypes or

have had one of the subtypes introduced, the receptors being human or

from a species that has been shown to have a similar pharmacology, and in

5   which assay the efficacy relative to a standard compound of the active

compound at the α2B or α2C receptor subtype is measured to be at least

0.3 greater than the efficacy relative to the standard compound of the active

compound at the α2A receptor subtype and its efficacy at the α2A receptor

subtype is ≤ 0.4, and/or the active compound is at least approximately 10

10   times more potent at the α2B or α2C receptor subtypes than at the α2A

receptor subtype.

90.   A process of claim 89 wherein approximately 0.001% to 5% by

weight of the active compound is administered topically to the host

15   mammal per day.

91.   A process for administering to a host mammal, including a human

being, a pharmaceutical composition containing an effective dose of an

active compound to treat or prevent muscle spasticity including

20   hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain

including neuropathic pain, neurodegenerative diseases including optic

neuropathy, spinal ischemia and stroke, memory and cognition deficits,

attention deficit disorder, psychoses including manic disorders, anxiety,

depression, hypertension, congestive heart failure, cardiac ischemia and

25   nasal congestion without sedating or cardiovascular side effects, wherein

said compound has adrenergic activity and is a selective agonist of the α2B

113

or α2B /α2C adrenoceptor receptor subtype(s) in preference over the α2A adrenoceptor receptor subtype.

92.   A process for administering to a host mammal, including a human

5   being, a pharmaceutical composition containing an effective dose of an active compound, having adrenergic activity, to treat muscle spasticity including hyperactive micturition, diarrhea, diuresis, withdrawal syndromes, pain including neuropathic pain, neurodegenerative diseases including optic neuropathy, spinal ischemia and stroke, memory and

10   cognition deficits, attention deficit disorder, psychoses including manic disorders, anxiety, depression, hypertension, congestive heart failure, cardiac ischemia and nasal congestion without sedating or cardiovascular side effects wherein the active compound has the biological property that the compound is a selective agonist of α2B or α2B /α2C receptor subtype(s)

15   in preference over the α2A receptor subtype, said selectivity being measured in an assay using cells that naturally express the individual α2 subtypes or have had one of the subtypes introduced, the receptors being human or from a species that has been shown to have a similar pharmacology, and in which assay the efficacy relative to a standard

20   compound of the active compound at the α2B or the α2C receptor subtype is measured to be at least 0.3 greater than the efficacy relative to the standard compound of the active compound at the α2A receptor subtype and its efficacy at the α2A receptor is ≤ 0.4, and/or the active compound is at least approximately 10 times more potent at the α2B or α2C receptor

25   subtypes than at the α2A receptor subtype.

93.   A process for administering to a host mammal, including a human

being, a pharmaceutical composition containing an effective dose of an

active compound, having adrenergic activity, to treat muscle spasticity

including hyperactive micturition, diarrhea, diuresis, withdrawal

5   syndromes, pain including neuropathic pain, neurodegenerative diseases

including optic neuropathy, spinal ischemia and stroke, memory and

cognition deficits, attention deficit disorder, psychoses including manic

disorders, anxiety, depression, hypertension, congestive heart failure,

cardiac ischemia and nasal congestion without sedating or cardiovascular

10   side effects wherein the active compound has the biological property that

the compound is a selective agonist of $\alpha 2B$ or $\alpha 2B$ /$\alpha 2C$ receptor subtype(s)

in preference over the $\alpha 2A$ receptor subtype, said selectivity being

measured in an RSAT assay in which activation of the $\alpha 2A$ and $\alpha 2C$

receptor subtype by the test compound is compared to brimonidine and the

15      $\alpha 2B$ receptor subtype is compared to oxymetazoline and wherein the

respective $\alpha 2A$, $\alpha 2B$ and $\alpha 2C$ receptor subtypes are expressed in NIH-3T3

cells, and in which assay the efficacy relative to brimonidine of the active

compound at the $\alpha 2C$ receptor subtype or the efficacy relative to

oxymetazoline of the active compound at the $\alpha 2B$ receptor subtype is

20   measured to be at least 0.3 greater than the efficacy relative to brimonidine

of the active compound at the $\alpha 2A$ receptor subtype, and its efficacy at the

$\alpha 2A$ receptor subtype is ≤ 0.4 and/or the active compound is at least

approximately 10 times more potent at the $\alpha 2B$ or $\alpha 2C$ receptor subtypes

than at the $\alpha 2A$ receptor subtype.

25

94.   A process of claim 74 wherein the active compound is at least one hundred times more potent at the α2B or α2C adrenoceptor subtype than at the α2A adrenoceptor subtype.

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6   C07D233/56   A61K31/415   C07D401/06   C07D403/06   C07D409/06
         C07D405/06   C07D233/84   C07D413/12   C07D495/04
         //(C07D495/04,335:00,333:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6   C07D   A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 07866 A (TOKYO TANABE CO MPANY LIMITED) 14 April 1994 see abstract	1-4, 18-27,37
X	WO 97 35858 A (ORTHO PHARMA CORP) 2 October 1997 see page 7; claims	1-4, 10-17,72
X	US 5 621 113 A (BOYD ROBERT E ET AL) 15 April 1997 see column 6; claims	1-4, 10-17,72
X	WO 97 12874 A (ORION-YHTYMÄ) 10 April 1997 see page 13 - page 15, line 2; claims	1-4, 18-30,72

-/--

[X] Further documents are listed in the continuation of box C.   [X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 March 1999	12/04/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Henry, J

1

INTERNATIONAL SEARCH REPORT

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 304 910 A (SEARLE & CO) 1 March 1989 see page 2, line 50 - page 4, line 20; claims	1-4,72
A	EP 0 194 984 A (CONTINENTAL PHARMA) 17 September 1986 see page 1 - page 2, line 15; claims	1-4,72
A	CHEMICAL ABSTRACTS, vol. 112, no. 15, 9 April 1990 Columbus, Ohio, US; abstract no. 139033n, page 721; XP002098179 see abstract & JP 01 242571 A (MITSUI PETROCHEMICAL INDUSTRIES LTD.) 27 September 1989	1-4,72

INTERNATIONAL SEARCH REPORT

Box I   Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:   85;86
   because they relate to subject matter not required to be searched by this Authority, namely:

   Remark: Although claims 85,86
           are directed to a method of treatment of the human/animal
           body, the search has been carried out and based on the alleged
           effects of the compound/composition.

2. [ ] Claims Nos.:
   because they relate to parts of the International Application that do not comply with the prescribed requirements to such
   an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II   Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all
       searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
       of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report
       covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
       restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9407866	A	14-04-1994	AU	5118493 A	26-04-1994
			JP	6192233 A	12-07-1994
WO 9735858	A	02-10-1997	US	5750720 A	12-05-1998
			AU	2422997 A	17-10-1997
			NO	984481 A	23-11-1998
US 5621113	A	15-04-1997	AU	2544097 A	17-10-1997
			EP	0889891 A	13-01-1999
			NO	984482 A	24-11-1998
			WO	9735857 A	02-10-1997
WO 9712874	A	10-04-1997	AU	7132796 A	28-04-1997
			CA	2231535 A	10-04-1997
			CN	1198741 A	11-11-1998
			CZ	9801018 A	16-09-1998
			EP	0888309 A	07-01-1999
			LT	98057 A,B	25-09-1998
			LV	12108 A	20-08-1998
			NO	981496 A	02-04-1998
			PL	328167 A	18-01-1999
			SI	9620111 A	31-10-1998
EP 0304910	A	01-03-1989	US	4882343 A	21-11-1989
			JP	1071871 A	16-03-1989
EP 0194984	A	17-09-1986	LU	85747 A	04-08-1986
			AT	51618 T	15-04-1990
			AU	597239 B	31-05-1990
			AU	5269686 A	31-07-1986
			CA	1273942 A	11-09-1990
			DK	39286 A	29-07-1986
			FI	860369 A	29-07-1986
			GR	860223 A	24-04-1986
			JP	61176571 A	08-08-1986
			PT	81910 B	13-05-1987
			US	4738979 A	19-04-1988